

AD _____

Award Number: DAMD17-99-1-9230

TITLE: Inhibition of Breast Cancer by Repression of Angiogenic
Hypoxia-Inducible Transcription Factors

PRINCIPAL INVESTIGATOR: Atul Bedi, M.D.

CONTRACTING ORGANIZATION: The Johns Hopkins University
School of Medicine
Baltimore, Maryland 21205-2196

REPORT DATE: September 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2000	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 99 - 31 Aug 00)	
4. TITLE AND SUBTITLE Inhibition of Breast Cancer by Repression of Angiogenic Hypoxia-Inducible Transcription Factors			5. FUNDING NUMBERS DAMD17-99-1-9230	
6. AUTHOR(S) Atul Bedi, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Johns Hopkins University School of Medicine Baltimore, Maryland 21205-2196 E-MAIL: rbedi@jhmi.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The key transcriptional regulators of the cellular hypoxic response, Hypoxia Inducible Factor-1 (HIF-1) and NF-κB, are responsible for induction of genes that regulate anaerobic metabolism, cell survival, and angiogenesis. We hypothesize that cancer cells subvert these normal hypoxia-dependent mechanisms to enable their own deregulated survival, neovasclogenesis, and growth. We propose that inhibition of HIF-1 and/or NF-κB can abrogate the angiogenic and apoptosis-resistant phenotype of breast tumors, thereby curtailing their growth and metastases. We find that loss of the p53 tumor suppressor function promotes the neovascularization and growth of tumor xenografts. Our results indicate that p53 inhibits NF-κB RelA activity via interaction with the p300 transcriptional integrator and promotes ubiquitin-mediated proteasomal degradation of the α subunit of HIF-1. Loss of p53 augments HIF-1- and NF-κB-dependent transcriptional activation of the vascular endothelial growth factor (<i>VEGF</i>) gene and contributes to the angiogenic switch during tumorigenesis. We are currently examining the effect of inhibiting HIF-1 and/or NF-κB on the growth, neovascularization, and metastatic potential of breast cancers <i>in vitro</i> and <i>in vivo</i> . The inhibition of breast cancers by repression of the key transcription factors governing adaptation to hypoxia, resistance to apoptosis, and angiogenesis could provide targets for innovative interventions to treat and prevent this disease.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 27	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

20010302 063

Table of Contents

	Page(s)
Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	10
Conclusions.....	10
References.....	11
Appendices.....	15

INTRODUCTION:

The clonal evolution of tumor cells in hypoxic microenvironments ultimately selects subpopulations that not only resist apoptosis, but also promote angiogenesis. The transcriptional regulators of the normal hypoxic response, Hypoxia Inducible Factor-1 (HIF-1) and NF- κ B, are responsible for induction of genes that promote anaerobic metabolism, cell survival, vasodilatation, and angiogenesis. We hypothesize that cancer cells subvert these normal hypoxia-dependent mechanisms to enable their own deregulated survival, neovasculogenesis, and growth. We propose that inhibition of HIF-1 and/or NF- κ B can abrogate the angiogenic and apoptosis-resistant phenotype of breast tumors, thereby curtailing their growth and metastases. We aim to elucidate the molecular mechanisms by which the p53 tumor suppressor regulates HIF-1 and NF- κ B activity and examine the effect of inhibiting HIF-1 and/or NF- κ B on the growth, neovascularization, and metastatic potential of breast cancers *in vitro* and *in vivo*. These studies will provide insights into the molecular mechanisms governing the response to hypoxic stress and will determine whether their subversion by breast cancers is responsible for their angiogenic phenotype. The inhibition of breast cancers by repression of these key transcription factors could provide targets for innovative interventions to treat and prevent this disease.

BODY:

The current report covers the first year of the research project. The period (0-12 months) in the research proposal was devoted to the completion of Specific Aim 1 (Tasks 1 and 2 of the approved statement of work).

Specific Aim 1. Investigate the mechanism(s) of p53-mediated repression HIF-1 and its role in regulation of hypoxia-induced angiogenesis.

- A. Elucidate the molecular mechanism(s) responsible for p53-mediated repression of HIF-1 activity.
- B. Define the role of HIF-1 in the angiogenic phenotype conferred by p53-deficiency

Statement of Work (1-12 months)

- Task 1: Elucidate the molecular mechanism(s) responsible for p53-mediated repression of HIF-1 activity.
- Task 2: Define the role of HIF-1 in the angiogenic phenotype conferred by p53-deficiency

Research Accomplished:

We have completed the studies proposed in specific aim 1 (Tasks 1 and 2) and have published the results and conclusions in:

Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes & Development* 14:34-44, 2000. (Reprint of publication enclosed).

All the methodology and results (data and figures) detailed in the following summary are included in the publication referenced above (Please refer to the publication reprint in *Appendix 1*)

Abstract

The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that p53 promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1 α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of p53 in tumor cells enhances HIF-1 α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (VEGF) gene in response to hypoxia. Forced expression of HIF-1 α in p53-expressing tumor cells increases hypoxia-induced VEGF expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis.

Regions of vascular deficiency or defective microcirculation in growing tumors are deprived of O₂, glucose, and other nutrients. Apoptosis induced by nutrient deficiency counterbalances cell proliferation and limits

tumor growth (Holmgren et al., 1995; O'Reilly et al., 1996; Parangi et al., 1996). Clonal evolution of tumor cells in this hypoxic microenvironment results from selection of sub-populations that not only resist apoptosis (Graeber et al., 1996), but also promote the formation of new blood vessels (reviewed by Folkman, 1997; Hanahan and Folkman, 1996). In addition to promoting further growth of the primary tumor, cellular adaptation to hypoxia and tumor neovascularization strongly correlate with the risk of invasion and metastasis (reviewed by Brown and Giaccia, 1998; Dang and Semenza, 1999; Folkman, 1997). The switch to an angiogenic phenotype is considered to be a fundamental determinant of neoplastic progression (Bergers et al., 1999; Folkman et al., 1989; Gimbrone et al., 1972). This realization has, in turn, fueled an intense search for the molecular mechanisms by which the angiogenic switch is activated during tumorigenesis.

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that regulates O₂ homeostasis and physiologic responses to O₂ deprivation (reviewed by Guillemin and Krasnow, 1997; Semenza, 1999). HIF-1 consists of two subunits, HIF-1 α and HIF-1 β , that belong to a subfamily of basic helix-loop-helix (bHLH) transcription factors containing a PAS (Per-ARNT-Sim) motif (Wang et al., 1995). A decrease in cellular O₂ tension leads to elevation of HIF-1 activity via stabilization of the HIF-1 α protein; conversely, ubiquitin-mediated proteolysis of HIF-1 α upon re-exposure to a normoxic environment results in rapid decay of HIF-1 activity (Huang et al., 1998; Kallio et al., 1999; Salceda and Caro, 1997; Semenza and Wang, 1992; Wang et al., 1995). The binding of HIF-1 α , in conjunction with its dimerization partner HIF-1 β , to DNA (consensus binding sequence, 5'-RCGTG-3') leads to the transcriptional activation of genes that mediate anaerobic metabolism (glucose transporters and glycolytic enzymes), O₂-carrying capacity (erythropoietin, transferrin), and vasodilatation (inducible nitric oxide synthase and heme oxygenase-1) (reviewed by Guillemin and Krasnow, 1997; Semenza, 1999). HIF-1 also binds to the 5' flanking sequence of the vascular endothelial growth factor (*VEGF*) gene, and is required for transactivation of *VEGF* in response to hypoxia (Carmeliet et al., 1998; Forsythe et al., 1996; Iyer et al., 1998; Ryan et al., 1998). The binding of VEGF to the receptor tyrosine kinases flk1/KDR, flt-1, and flt-4 (VEGFR-1-3), on vascular endothelial cells promotes their proliferation and leads to vessel formation (reviewed by Brown et al., 1996; Ferrara, 1993; Risau and Flamme, 1995). In contrast to wild-type cells, *VEGF* gene expression is not induced by hypoxia in HIF-1 α -deficient embryonic stem cells, and dramatic vascular regression occurs in HIF-1 α -null mouse embryos (Iyer et al., 1998; Kottch et al., 1999). Therefore, HIF-1 is a key transcriptional mediator of metabolic adaptation and VEGF-mediated angiogenesis in response to hypoxia. While these responses serve to maintain O₂ homeostasis in normal tissues, they are also co-opted by tumors to facilitate neovascularization and growth. Akin to their role in vascular development and remodeling in normal tissues, HIF-1 α (Carmeliet et al., 1998; Maxwell et al., 1997; Ryan et al., 1998) and VEGF (Kim et al., 1993; Millauer et al. 1994; Plate et al., 1992; Shweiki et al., 1992) facilitate tumor angiogenesis, and both HIF-1 α (Zhong et al., 1999) and VEGF (reviewed by Folkman, 1997) are overexpressed in a wide variety of human cancers.

The genetic alterations that are responsible for oncogenesis and tumor progression may also underlie the ability of tumors to switch to an angiogenic phenotype. The human *p53* tumor suppressor gene encodes a multifunctional transcription factor that mediates cellular responses to diverse stimuli, including DNA damage and hypoxia (reviewed by Giaccia and Kastan, 1998). In addition to being an integral component of the surveillance mechanisms that arrest cell cycle progression under adverse conditions, *p53* is also involved in mediating hypoxia-induced apoptosis (Graeber et al., 1996), and inducing inhibitors of angiogenesis, such as thrombospondin-1 (Dameron et al., 1994; Van Meir et al., 1994). Evidence also suggests that *p53* negatively regulates *VEGF* expression (Bouvet et al., 1998; Fontanini et al., 1998; Mukhopadhyay et al., 1995). Somatic mutations of the *p53* gene represent one of the most common genetic alterations in human cancers, and the acquisition of such defects is strongly associated with tumor progression and metastasis (reviewed by Levine, 1997).

In this study, we demonstrate that genetic inactivation of *p53* in cancer cells provides a potent stimulus for tumor angiogenesis and identify a novel mechanism by which loss of *p53* function contributes to activation of the angiogenic switch in tumors. We find that homozygous deletion of *p53* via homologous recombination in human cancer cells promotes the neovascularization and growth of tumor xenografts in nude mice. We show that *p53* inhibits HIF-1 activity by targeting the HIF-1 α subunit for Mdm2-mediated ubiquitination and proteasomal degradation. Conversely, the loss of *p53* enhances hypoxia-induced HIF-1 α levels and augments HIF-1-dependent expression of VEGF in tumor cells. We further demonstrate that forced expression of HIF-1 α in *p53*-expressing tumor cells promotes VEGF expression and neovascularization of tumor xenografts. These findings indicate that inactivation of *p53* in tumor cells contributes to activation of the angiogenic switch via amplification of normal HIF-1-dependent responses to hypoxia.

Results

Inhibition of tumor angiogenesis and growth by p53

The effect of p53 on tumor cell growth and angiogenesis was examined by comparing an isogenic set of human adenocarcinoma cell lines differing only in their p53 status (Bunz et al., 1998). The parental HCT116 line, containing wild-type p53 (p53^{+/+}), and a p53-deficient derivative (p53^{-/-}), generated by homologous recombination, demonstrated equivalent growth kinetics in tissue culture, with doubling times of 29 and 32 h, respectively (Figure 1A). However, xenografts (2.5×10^4 – 2.5×10^5 cells) of p53^{-/-} HCT116 cells in athymic BALB/c (nu/nu) mice exhibited a significantly shorter latency and marked increase in tumor growth kinetics compared to their p53^{+/+} counterparts (Figure 1B and C). While 12/12 animals inoculated with 2.5×10^4 p53^{-/-} cells developed tumors within 3 weeks, only 1/12 mice receiving the same number of p53^{+/+} cells was able to establish a tumor during the entire 8-week observation period. To examine whether the observed differences in growth kinetics in vivo were associated with variation in tumor vascularity, tumors established from p53^{+/+} and p53^{-/-} cells were subjected to histologic analysis and nuclear magnetic resonance (NMR) imaging. Immunohistochemical analyses of tumor sections using an antibody against von Willebrand Factor (vWF) demonstrated significantly increased blood vessel density in p53^{-/-} tumors compared to their p53^{+/+} counterparts (Figure 1D and E). Analyses of neovascularization by NMR imaging showed that compared to p53^{+/+} tumors, p53^{-/-} tumors had a higher vascular volume (14 ± 2.6 μ l/g versus 8.4 ± 2.4 μ l/g in highly permeable regions), as well as a three-fold greater vascular permeability (0.4 ± 0.18 μ l/g/min versus 0.13 ± 0.04 μ l/g/min in highly vascular zones) (Figure 1F). Thus, loss of p53 function has a profound effect on the neovascularization and growth of human colorectal cancer xenografts in nude mice.

Effect of p53 genotype on hypoxia-induced VEGF expression and HIF-1 activity

Hypoxia-induced, HIF-1-mediated expression of VEGF stimulates angiogenesis and vascular permeability in neoplastic tissues (Carmeliet et al., 1998; Forsythe et al., 1996; Maxwell et al., 1997; Plate et al., 1992; Shweiki et al., 1992). p53^{+/+} and p53^{-/-} HCT116 cells were analyzed for expression of VEGF mRNA and protein under tissue culture conditions simulating the hypoxic tumor microenvironment. Following exposure to 1% O₂, p53^{-/-} cells exhibited a greater induction of VEGF mRNA and protein compared to their p53^{+/+} counterparts (Figure 2A and B). Transcriptional activation of the *VEGF* gene in response to hypoxia is mediated by binding of HIF-1 to a 47-bp hypoxia-response element in the 5' flanking region, and a reporter plasmid containing this sequence (VEGF-p11w) is transactivated by cotransfection of an expression vector encoding HIF-1 α (pCEP4/HIF-1 α) (Forsythe et al., 1996). To examine whether p53 influences HIF-1-mediated transcriptional activation of VEGF, p53^{+/+} and p53^{-/-} cells were cotransfected with the VEGF-p11w reporter and CMV β gal [encoding β -galactosidase (β -gal)]. Analyses of luciferase and β -gal activity in response to hypoxia (1% O₂) revealed a four-fold greater increase in VEGF-p11w transcription (relative to β -gal) in p53^{-/-} cells compared to p53^{+/+} cells (Figure 2C). These differences were not seen when the reporter contained a 3-bp substitution in the hypoxia response element that eliminated HIF-1 binding (VEGF-p11m), suggesting that HIF-1 was a target for p53-mediated inhibition. Coexpression of pCEP4/HIF-1 α in p53^{+/+} cells increased hypoxia-induced activation of VEGF-p11w to levels that approached the reporter activity exhibited by hypoxic p53^{-/-} cells in the absence of exogenous HIF-1 α (Figure 2C). Conversely, cotransfection of an expression vector encoding wild-type human p53 into p53^{-/-} cells completely repressed hypoxia-induced VEGF-p11w expression (Figure 2C). Electrophoretic mobility shift assays demonstrated that hypoxia-induced HIF-1 DNA-binding activity was reduced in p53^{+/+} cells compared to p53^{-/-} cells (Figure 2D). The specificity of binding of HIF-1 to DNA was confirmed by competing hypoxia-induced DNA-protein complexes with excess unlabeled wild-type probe but not with an unlabeled mutant probe containing the same 3-bp substitution in the HIF-1 binding site as in reporter VEGF-p11m. Thus, p53 inhibits HIF-1 activity and VEGF expression in response to hypoxia.

Effect of p53 on oxygen-regulated expression and stability of HIF-1 α

Hypoxia-induced HIF-1 DNA-binding and transcriptional activity are dependent upon increased levels of HIF-1 α protein and its heterodimerization with HIF-1 β (Huang et al., 1998; Jiang et al., 1996; Wang et al., 1995; Wang and Semenza, 1993). To investigate whether p53 influences HIF-1 activity by altering expression of HIF-1 α , the levels of HIF-1 α protein and mRNA were assessed in p53^{+/+} and p53^{-/-} cells exposed to either 20% or 1% O₂. In response to hypoxia, p53^{-/-} HCT116 cells or mouse embryonic fibroblasts (MEFs) expressed higher levels of HIF-1 α protein compared to their p53^{+/+} counterparts (Figure 3A and B). In contrast to HIF-1 α protein levels, HIF-1 α mRNA was expressed at equivalent levels in hypoxic p53^{+/+} and p53^{-/-} cells (Figure 3C), suggesting an effect of p53 on HIF-1 α protein expression. To confirm this effect, p53^{-/-} cells were cotransfected with pCEP4-HIF-1 α and either pCMV-p53 (encoding wild-type human p53) or empty vector (pCMV0), and exposed to 1% O₂ for 8 h. Immunoblot analysis showed that p53^{-/-} cells cotransfected with pCMV-p53 exhibited reduced levels of HIF-1 α compared to cells receiving the control vector (Figure 3D).

The steady state level of HIF-1 α protein is regulated by an oxygen-dependent and iron-sensitive mechanism of ubiquitin-mediated proteasomal degradation (Huang et al., 1998; Kallio et al., 1999; Salceda and Caro, 1997). The 20S proteasome is the core catalytic subunit of the 26S proteasome complex that mediates degradation of ubiquitin-tagged proteins (reviewed by Herskho and Ciechanover, 1998). HIF-1 α expression is induced by exposure to hypoxia or treatment with cobalt chloride (Wang et al., 1995). To examine whether p53 influences the stability of HIF-1 α protein, HIF-1 α expression was analyzed in lysates of cobalt-treated p53^{+/+} and p53^{-/-} cells at serial time intervals following addition of cycloheximide. HIF-1 α protein decayed with a half-life of less than 20 min in p53^{+/+} cells, compared with more than 40 min in p53^{-/-} cells (Figure 3E).

HPV-E6 augments HIF-1 α stability and VEGF expression in response to hypoxia.

The human papilloma virus (HPV16) E6 oncoprotein promotes ubiquitin-dependent conjugation and degradation of p53 (Scheffner et al., 1990). To investigate whether E6-induced degradation of endogenous p53 promotes expression of HIF-1 α and induction of VEGF, the PA-1 carcinoma cell line was stably transfected with an expression vector encoding HPV-16 E6 (PA-1 E6) or empty vector (PA-1 Neo) (Ravi et al., 1998). Under hypoxic conditions, PA-1 E6 cells expressed higher levels of HIF-1 α protein compared to PA-1 Neo cells (Figure 4A). Analyses of HIF-1 α protein stability in cycloheximide-treated cells showed that HIF-1 α protein decayed with a half-life of ~ 15 min in PA-1 cells, compared with more than 30 min in PA-1 E6 cells (Figure 4B). PA-1 Neo or PA-1 E6 cells were cotransfected with either VEGF-p11w or VEGF-p11m reporter and CMV β gal. Analyses of luciferase and β -gal activity in response to hypoxia (1% O₂) revealed a two-fold greater increase in VEGF-p11w transcription (relative to β -gal) in PA-1 E6 cells compared to PA-1 Neo cells (Figure 4C). Neither cell line exhibited significant transcription of the VEGF-p11m reporter. Consistent with the promotion of HIF-1-dependent VEGF transcription by E6 expression, exposure to 1% O₂ resulted in greater induction of VEGF protein expression in PA-1 E6 cells compared to PA-1 Neo cells (Figure 4D).

p53 promotes ubiquitin-dependent degradation of HIF-1 α

To determine whether p53 interacts with HIF-1 α in HCT116 cells, as previously demonstrated in MCF-7 cells (An et al., 1998), protein lysates from hypoxic p53^{+/+} and p53^{-/-} cells were immunoprecipitated with an anti-p53 or isotype control antibody, and the resulting immune complexes were subjected to immunoblot assays using an antibody against HIF-1 α . HIF-1 α was detected in immunoprecipitates derived from p53^{+/+} cells but not p53^{-/-} cells or immune complexes precipitated with the control antibody (Figure 5A).

To determine whether p53 promotes ubiquitination of HIF-1 α , p53^{+/+} and p53^{-/-} cells were cotransfected with an HIF-1 α expression vector (pCEP4/HIF-1 α) and a vector encoding hexahistidine-tagged ubiquitin (His₆-Ub), or the empty control vectors. Transfected cells were exposed to 1% O₂ for 4 h in the presence of MG132, a peptide aldehyde inhibitor of the 20S proteasome. Aliquots of whole cell extracts or His-tagged proteins isolated by affinity purification from cell lysates were subjected to immunoblot assays using an anti-HIF-1 α monoclonal antibody (Figure 5B). Immunoblot analysis of whole cell extracts of p53^{+/+} cells detected a 120-kD protein corresponding to the apparent molecular mass of HIF-1 α (Wang et al., 1995), as well as an additional series of slower migrating complexes. The higher molecular weight complexes represented polyubiquitinated forms of HIF-1 α since they were also detected by immunoblot analysis of His-tagged proteins with an anti-HIF-1 α monoclonal antibody. Compared to p53^{+/+} cells, p53^{-/-} cells transfected with vectors encoding HIF-1 α and His₆-Ub demonstrated a higher level of unconjugated HIF-1 α and a reciprocal reduction in polyubiquitinated HIF-1 α (Figure 5B). Introduction of a p53 expression vector (pCMV-p53) into p53^{-/-} cells increased the proportion of HIF-1 α that was ubiquitinated under hypoxic conditions (Figure 5B).

Conjugation of Ub to proteins destined for degradation involves conversion of Ub to a high-energy thiol ester by the E1 Ub-activating enzyme followed by the transfer of activated Ub to the substrate via the activity of an E2 Ub-conjugating enzyme and an E3 Ub-protein ligase (reviewed by Herskho and Ciechanover, 1998). To confirm the requirement of the Ub-proteasome system for p53-mediated degradation of HIF-1 α , we examined the effect of p53 on hypoxia-induced HIF-1 α expression in the BALB/c 3T3-derived ts20TG^R cell line which harbors a thermolabile E1, or a derivative cell line (H38-5) in which the temperature sensitive defect was corrected by introduction of the human E1 cDNA (Chowdary et al., 1994). ts20TG^R and H38-5 cells were transfected with either an expression vector encoding human p53 or a control vector and transferred to hypoxic chambers (1% O₂) at either the permissive temperature (35°C) or the restrictive temperature (39°C). Transfection of p53 into ts20TG^R cells resulted in reduced HIF-1 α levels at 35°C but not at 39°C (Figure 5C). However, E1-expressing H38-5 cells exhibited p53-mediated reduction of HIF-1 α levels at both temperatures. Taken together, the data indicate that p53 limits hypoxia-induced expression of HIF-1 α by promoting its ubiquitination and proteasomal degradation.

While a single E1 is responsible for activation of ubiquitin, multiple E3 enzymes are responsible for specific selection of proteins destined for degradation. Since p53 induces the Mdm2 E3 Ub-protein ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 (Barak et al., 1993; Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Momand et al., 1992; Wu et al., 1993), this raised the possibility that HIF-1 α is recruited to Mdm2 via its interaction with p53. To test this hypothesis, protein lysates of p53^{-/-} HCT116 cells that were transfected with either pCMV-p53 or empty vector and transferred to 1% O₂ for 6 h were immunoprecipitated with anti-Mdm2 or isotype control antibody, and the resulting immune complexes were subjected to immunoblot assays using an antibody against HIF-1 α . Anti-Mdm2 immunoprecipitates derived from cells transfected with p53 displayed significantly higher levels of co-precipitated HIF-1 α protein compared to immune complexes derived from p53^{-/-} HCT116 cells with the empty vector (Figure 5D).

Amino acid residues Phe-19, Leu-22, and Trp-23 in the amino-terminal transactivation domain of p53 are critical for its interaction with Mdm2 (Lin et al., 1994; Kussie et al., 1996). A p53 double mutant at residues 22 and 23 (p53 Gln22,Ser23) fails to interact with Mdm2 and is also transactivation-deficient (Lin et al., 1994). A p53 mutant carrying a deletion of residues 13-19 (p53 Δ I), is also unable to bind to Mdm2 but retains its transactivation function (Marston et al., 1994). To investigate whether p53 requires interaction with Mdm2 to mediate degradation of HIF-1 α , p53^{-/-} HCT116 cells were transfected with expression vectors encoding either wt p53, p53 Gln22,Ser23, p53 Δ I, or control vector, and analyzed for HIF-1 α expression under hypoxic conditions. In contrast to wt p53, the p53 mutants (p53 Δ I or p53 Gln22,Ser23) or the control vector were unable to reduce the levels of HIF-1 α (Figure 5E).

The Ub-protein ligase function of Mdm2 is dependent upon a RING finger domain (residues 434-490) at the carboxyl terminus (Honda et al., 1997). Mdm2 mutants with a deletion of the RING finger domain [Mdm2 (1-440)] or a substitution of a cysteine residue at position 464 to alanine [Mdm2 (464Ala)] are deficient in Ub-protein ligase function but retain the ability to bind p53, thereby behaving in a dominant negative manner (Kubbutat et al., 1999). Introduction of Mdm2 (1-440) or Mdm2 (464Ala) augmented hypoxia-induced HIF-1 α levels in p53^{+/+} HCT116 cells, but did not significantly influence HIF-1 α expression in hypoxic p53^{-/-} HCT116 cells (Figure 5F). To determine whether Mdm2 functions as an E3-ligase that mediates p53-induced degradation of HIF-1 α , ts20TG^R and H38-5 cells were cotransfected with expression vectors encoding wt p53 and either Mdm2 (1-440) or empty control vector and transferred to hypoxic chambers (1% O₂) at 39°C. Cotransfection of Mdm2 (1-440) increased hypoxia-induced HIF-1 α expression in E1-proficient H38-5 cells coexpressing p53 to levels observed in E1-deficient ts20TG^R cells (Figure 5G). Together, the data in Figure 5 are consistent with a model in which p53 acts as a molecular chaperone that facilitates recognition and/or recruitment of HIF-1 α for ubiquitination by Mdm2.

Enhancement of tumor angiogenesis in p53^{+/+} cells by forced expression of HIF-1 α

To determine whether p53-mediated degradation of HIF-1 α contributes to the suppression of tumor angiogenesis and growth, p53^{+/+} HCT116 cells were stably transfected with pCEP4/HIF-1 α (HCT116-HIF-1 α) (Figure 6A). Under hypoxic conditions, stable transfectants overexpressing HIF-1 α demonstrated significantly increased VEGF mRNA levels compared to the parental p53^{+/+} cells (Figure 6B). When inoculated into athymic nude mice, HCT116-HIF-1 α cells established tumors with a shorter latency and exhibited a significant increase in tumor growth kinetics compared to the parental cells (Figure 6C). Histologic evaluation and analyses of NMR maps, as described earlier, revealed a significant increase in blood vessel density, vascular volume (17.4 μ l/g) and permeability (0.8 μ l/g/min) in xenografts established from HCT116-HIF-1 α cells compared to those derived from the parental p53^{+/+} HCT116 cells (Figure 6D).

Discussion

Recognition of the importance of angiogenesis for the growth and metastasis of cancers has raised fundamental questions regarding the molecular mechanisms of the angiogenic switch during tumor progression. The genetic alterations involved in tumorigenesis are also responsible for the phenotypic characteristics of cancer cells. The p53 tumor suppressor gene is one of the most frequently mutated genes in human cancers (reviewed by Levine, 1997). In addition to p53 mutations, which occur in ~50% of all cancers (involving more than 50 tissue types), p53 is also inactivated by viral oncoproteins such as the E6 protein of cervical cancer-associated HPV 16 and 18, adenovirus E1A, and SV40 large-T antigen (reviewed by Levine, 1997). Our observations indicate that loss of p53 function, via somatic mutations or expression of viral oncoproteins, contributes to activation of the angiogenic switch during tumorigenesis.

In addition to identifying the loss of p53 as a discrete and potentially rate-limiting event in tumor angiogenesis, we define a novel mechanism by which p53 regulates the angiogenic switch. Our observations indicate that p53 inhibits hypoxia-induced expression of HIF-1 α by facilitating its ubiquitination and subsequent

degradation. This mechanism is distinct from the proposal that p53 inhibits HIF-1-mediated transactivation by competing for the p300 coactivator (Blagosklonny et al., 1998), and is analogous to the proposed role of the von Hippel-Lindau (VHL) tumor suppressor (Maxwell et al., 1999). As in the case of VHL (Maxwell et al., 1999), we demonstrate that p53 interacts with HIF-1 α in vivo, as previously reported (An et al., 1998). In addition, we demonstrate for the first time that a tumor suppressor (p53) promotes the ubiquitin-mediated degradation of HIF-1 α via recruitment of an E3 ubiquitin-protein ligase (Mdm2). While ubiquitination is assumed to be the mechanism by which VHL affects HIF-1 α degradation, our data provide the first direct evidence for this mechanism of tumor suppressor action. The constitutive stabilization of HIF-1 α (and the related HIF-2 α protein) resulting from VHL loss-of-function may underlie the predisposition to highly angiogenic tumors in VHL disease, a rare hereditary cancer syndrome. Our findings indicate that deregulation of HIF-1 α expression, leading to overexpression of VEGF, may contribute to the angiogenic switch conferred by inactivation of p53 in a broad array of human cancers. In accordance with this hypothesis, HIF-1 α is frequently overexpressed in common human cancers and there is a statistically significant correlation between the presence of mutant p53 and HIF-1 α overexpression (Zhong et al., 1999). Our findings suggest that increased HIF-1 activity resulting from loss of p53 function may contribute to the overexpression of VEGF that is observed in a wide variety of human cancers (reviewed by Brown et al., 1996; Folkman, 1997).

The angiogenic switch is regulated by changes in the relative balance between inducers and inhibitors of endothelial cell proliferation and migration (reviewed by Hanahan and Folkman, 1996). The switch can be activated by increasing the levels of inducers, such as VEGF, and/or by reducing the concentration of inhibitors, such as thrombospondin-1 (TSP-1). The p53-mediated inhibition of VEGF expression demonstrated in this study, together with the previously reported ability of p53 to upregulate TSP-1 (Dameron et al., 1994), indicates that p53 provides dual functions that regulate angiogenesis. Thus, the loss of p53 function during tumorigenesis deregulates both arms of the balance, providing a potent stimulus for neovascularization and tumor progression.

In addition to loss of function mutations in tumor suppressor genes such as *p53* or *VHL*, oncogene activation is also capable of stimulating HIF-1 activity. Expression of the *v-Src* oncogene induces expression of HIF-1 α protein, HIF-1 DNA-binding activity, and transcriptional activation of *VEGF* and *enolase 1* (Jiang et al., 1997). A phosphatidylinositol 3-kinase/Akt pathway of HIF-1 activation may induce VEGF expression in *Ha-ras*-transformed cells (Mazure et al., 1996). Therefore, increased HIF-1 expression is associated with multiple genetic alterations that promote tumor angiogenesis. Since HIF-1 is also a key transcriptional activator of genes encoding glucose transporters and glycolytic enzymes (Iyer et al., 1998), these genetic alterations also contribute to the metabolic adaptation and enhanced survival of tumor cells in hypoxic microenvironments.

As p53 is an important mediator of DNA damage-induced apoptosis, the angiogenic phenotype conferred by inactivation of p53 in human cancers is frequently associated with resistance to conventional genotoxic anticancer agents (reviewed by Lowe, 1995). Since p53-deficient tumors remain dependent upon angiogenesis for growth and metastasis, inhibition of angiogenesis may represent an effective therapeutic intervention (Bergers et al., 1999; Boehm et al., 1997). Recent studies indicate that inhibition of tumor-derived VEGF expression restricts angiogenesis and promotes vascular regression in experimental tumor models (Goldman et al., 1998; Kim et al., 1993; Millauer et al., 1994, 1996; Warren et al., 1995). Loss of HIF-1 activity is also associated with decreased angiogenesis and growth of tumor xenografts in nude mice (Carmeliet et al., 1998; Jiang et al., 1997; Maxwell et al., 1997; Ryan et al., 1998). By demonstrating that deregulation of HIF-1 underlies the increased expression of VEGF in p53-deficient cancers, our data provide further support for the hypothesis that inhibition of HIF-1 may abrogate the ability of such tumors to establish an adequate vascular supply and adapt their cellular metabolism to hypoxia, thereby curtailing their growth and metastasis.

KEY RESEARCH ACCOMPLISHMENTS:

- Our observations indicate that loss of p53 function, via somatic mutations or expression of viral oncoproteins, contributes to activation of the angiogenic switch and promotes tumor growth.
- Our studies define a novel mechanism by which p53 regulates the angiogenic switch; p53 inhibits hypoxia-induced expression of HIF-1 α by facilitating its ubiquitination and subsequent degradation.
- Our findings suggest that amplification of HIF-1 activity resulting from loss of p53 function may contribute to the overexpression of VEGF that is observed in a wide variety of human cancers.

REPORTABLE OUTCOMES:

We have completed the studies proposed in specific aim 1 (Tasks 1 and 2) and have published the results and conclusions in:

Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes & Development* 14:34-44, 2000. (Reprint of publication enclosed).

These findings were presented (abstract & poster) at the AACR-NCI-EORTC Meeting in Washington, D.C., 1999.

Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Abstract & Presentation at AACR-NCI-EORTC Meeting*, Washington, D.C., Nov. 1999.

CONCLUSIONS:

Importance of completed research:

There are two major impediments to the successful treatment of breast cancer. First, surgical extirpation of the primary neoplasm is often followed by the occurrence of metastatic tumors. Second, overt metastases are resistant to conventional chemo- or radio-therapy. Therefore, successful treatment is contingent upon identifying strategies to prevent metastases or eliminate tumor cells that have acquired genetic aberrations that confer resistance to cytotoxic agents. Several lines of evidence suggest that the inhibition of tumor angiogenesis may serve both functions. Since angiogenesis is also a necessary component of tumor growth, the inhibition of this process may also serve to prevent the growth of primary tumors beyond a limited zone determined by the vascular supply. As such, it may be applied to prevent breast cancers in genetically susceptible high-risk populations.

Implications and practical applications of completed research:

Strategies to inhibit angiogenesis have hitherto focused upon inhibition of individual angiogenic factors/receptors or suppression of endothelial cell proliferation. Unlike these approaches which target downstream mediators of angiogenesis, strategies that target the proximal transcriptional mediators of angiogenesis and cell survival (HIF-1 or NF- κ B) would be expected to inhibit an entire panel of synergizing factors. As such, it may be more potent and less susceptible to evasion by genetically pliable tumor cells that could evolve mechanisms of resistance against any individual factor. By demonstrating that deregulation of HIF-1 contributes to the increased expression of VEGF in p53-deficient cancers, our data provide further support for the hypothesis that inhibition of HIF-1 may abrogate the ability of such tumors to establish an adequate vascular supply and adapt their cellular metabolism to hypoxia, thereby curtailing their growth and metastasis. These findings provide the foundation for the development of small molecule inhibitors of HIF-1 for anticancer therapy.

Future Studies:

As defined in the research proposal and approved statement of work, we have initiated studies devoted to the subsequent specific aims of the research project:

- Specific Aim 2. Define the role of NF- κ B RelA in the angiogenic phenotype conferred by p53 deficiency and the molecular determinants of κ B-dependent angiogenesis
- A. Investigate whether repression of RelA by a transdominant mutant I κ B α (I κ B α M) can inhibit the angiogenic phenotype conferred by p53- deficiency.
 - B. Investigate the molecular determinants of NF- κ B-mediated angiogenesis.
- Specific Aim 3. Examine the effect of inhibiting HIF-1 or RelA on growth, neovascularization, and metastatic potential of breast cancers.

REFERENCES:

- An, W.G., Kanekal, M., Simon, M.C., Maltepe, E., Blagosklonny, M.V., and Neckers, L.M. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1 α . *Nature* **392**: 405-408.
- Barak, Y., Juven, T., Haffner, R., and Oren, M. 1993. Mdm-2 expression is induced by wild type p53 activity. *EMBO J.* **12**: 461-468.
- Bergers, G., Javaherian, K., Lo, K.N., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science* **284**: 808-812.
- Blagosklonny, M.V., An, W.G., Romanova, L.Y., Trepel, J., Fojo, T., and Neckers, L. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. *J Biol Chem* **273**: 11995-11998.
- Boehm, T., Folkman, J., Browder, T., and O'Reilly, M.S. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. *Nature* **390**: 404-407.
- Bouvet, M., Ellis, L.M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C.D., Fang, B., Lee, J.J., and Roth, J.A. 1998. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. *Cancer Res.* **58**: 2288-92.
- Brown, L.F., Detmar, M., Claffey, K., Nagy, J.A., Feng, D., Dvorak, A.M., and Dvorak, H.M. 1996. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In *Control of angiogenesis*, (ed. I.D. Goldberg and E. Rosen), Birkhauser Verlag, Berlin.
- Brown, J.M. and Giaccia, A.J. 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res.* **58**: 1408.
- Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* **282**: 1497-1501.
- Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D., and Keshet, E. 1998. Role of HIF-1 α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* **394**: 485-490.
- Chowdary, D.R., Dermody, J.J., Jha, K.K. and Ozer, H.L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. *Mol. Cell. Biol.* **14**: 1997-2003.
- Dameron, K.M., Volpert, O.V., Tainsky, M.A. and Bouck, N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* **265**: 1582-1584.
- Dang, C.V. and Semenza, G.L. 1999. Oncogenic alterations of metabolism. *Trends Biochem. Sci.* **24**: 68-72.
- Ferrara, N. 1993. Vascular endothelial growth factor. *Trends Cardiovasc. Med.* **3**: 244-250.
- Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* **339**: 58-61.
- Folkman, J. 1997. Tumor angiogenesis. In *Cancer Medicine* (ed. J.F. Holland, R.C. Bast, Jr., D.L. Morton, E. Frei III, D.W. Kufe, and R.R. Weichselbaum), pp 181-204. Williams & Wilkins, Baltimore, MD.
- Fontanini, G., Boldrini, L., Vignati, S., Chine, S., Basolo, F., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C.A., and Bevilacqua, G. 1998. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. *Eur J Cancer* **34**: 718-23.

- Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., and Semenza, G.L. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol. Cell. Biol.* **16**: 4604-4613.
- Freedman, D.A., Wu, L., and Levine, A.J. 1999. Functions of the MDM2 oncoprotein. *Cell. Mol. Life Sci.* **55**: 96-107.
- Giaccia, A.J. and Kastan, M.B. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev.* **12**: 2973-2983.
- Gimbrone, M.A.J., Leapman, S.B., Cotran, R.S., and Folkman, J. 1972. Tumor dormancy in vivo by prevention of neovascularization. *J. Exp. Med.* **136**: 261-276.
- Goldman, C.K., Kendall, R.L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G.Y., Siegal, G.P., Mao, X., Bett, A.J., Huckle, W.R., Thomas, K.A., and Curiel, D.T. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. *Proc Natl Acad Sci USA* **95**: 8795-8800.
- Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and Giaccia, A.J. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature* **379**: 88-91.
- Guillemin, K., and Krasnow, M.A. 1997. The hypoxic response: Huffing and HIFing. *Cell* **89**: 9-12.
- Hanahan, D. and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* **86**: 353-364.
- Haupt, Y., Maya, R., Kazaz, A., and Oren, M. 1997. Mdm2 promotes the rapid degradation of p53. *Nature* **387**: 299-303.
- Hershko, A. & Ciechanover, A. 1998. The ubiquitin system. *Annu. Rev. Biochem* **67**: 425-479.
- Holmgren, L., O'Reilly, M.S., and Folkman, J. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nature Med.* **1**: 149-153.
- Honda, R., Tanaka, H., and Yasuda, H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.*, **420**: 25-27.
- Huang, L.E., Gu, J., Schau, M. and Bunn, H.F. 1998. Regulation of hypoxia-inducible factor 1 α is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway. *Proc. Natl. Acad. Sci. USA* **95**: 7987-7992.
- Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H., Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., and Semenza, G.L. 1998. Cellular and developmental control of O₂ homeostasis by hypoxia inducible factor 1 α . *Genes Dev.* **12**: 149-162.
- Jiang, B.-H., Rue, E., Wang, G.L., Roe, R. and Semenza, G.L. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. *J. Biol. Chem.* **271**: 17771-17778.
- Jiang, B.H., Agani, F., Passaniti, A., and Semenza, G.L. 1997. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. *Cancer Res.* **57**: 5328-5335.
- Kallio, P.J., Wilson, W.J., O'Brien, S., Makino, Y. and Poellinger, L. 1999. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. *J. Biol. Chem.* **274**: 6519-6525.
- Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature* **362**: 841-844.

- Kotch, L.E., Iyer, N.V., Laughner, E., and Semenza, G.L. 1999. Defective vascularization of HIF-1 α -null embryos is not associated with VEGF deficiency but with mesenchymal cell death. *Dev Biol* **209**: 254-267.
- Kubbutat, H.M.G., Jones, S.N., and Vousden, K.H. 1997. Regulation of p53 stability by Mdm2. *Nature* **387**: 299-303.
- Kubbutat, M.H.G., Ludwig, R.L., Levine, A.J., and Vousden, K.H. 1999. Analysis of the degradation function of Mdm2. *Cell Growth & Differentiation* **10**: 87-92.
- Kubbutat, M.H.G., Ludwig, R.L., Ashcroft, M., and Vousden, K.H. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. *Mol. Cell. Biol.* **18**: 5690-5698.
- Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. *Cell* **88**: 323-331.
- Lin, J., Chen, J., Elenbaas, B., and Levine, A.J. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. *Genes & Dev.* **8**: 1235-1246.
- Lowe, S.W. 1995. Cancer therapy and p53. *Curr. Opin. Oncol.* **7**: 547-553.
- Marston, N.J., Jenkins, J.R., and Vousden, K.H. 1995. Oligomerisation of full-length p53 contributes to the interaction with mdm2 but not HPV E6. *Oncogene*, **10**: 1709-1715.
- Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., Hankinson, O., Pugh, C.W., and Ratcliffe PJ. 1997. Hypoxia-inducible factor 1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. *Proc. Natl. Acad. Sci. USA* **94**: 8104-8109.
- Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**: 271-275.
- Mazure, N.M., Chen, E.Y., Laderoute, K.R., and Giaccia, A.J. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. *Blood* **90**: 3322-3331.
- Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. *Nature* **367**: 576-579.
- Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A., and Strawn, L.M. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. *Cancer Res.* **56**: 1615-1620.
- Momand, J., Zambetti, G.P., George, D.L., and Levine, A.J. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell* **69**: 1237-1245.
- Mukhopadhyay, D., Tsiokas, L., and Sukhatme, V.P. 1995. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. *Cancer Res.* **55**: 6161-6165.
- Musti, A.M., Treier, M. and Bohmann, D. 1997. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. *Science* **275**: 400-402.
- O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. *Nature Med.* **2**: 689-692.
- Parangi, S., O'Reilly, M.S., Christofori, G., Holmgren, I., Grosfeld, J., Folkman, J., and Hanahan, D. 1996. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. *Proc. Natl. Acad. Sci. USA* **93**: 2002-2007.

Plate, K.H., Breier, G., Weich, H.A. and Risau, W. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. *Nature* **359**: 845-848.

Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., Bedi, A. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes & Development* **14**:34-44. (Reprint of publication enclosed).

Risau, W., and Flamme, I. 1995. Vasculogenesis. *Annu. Rev. Cell Dev. Biol.* **11**: 73-91.

Ryan, H.E., Lo, J. and Johnson, R.S. 1998. HIF-1 α is required for solid tumor formation and embryonic vascularization. *EMBO J.* **17**: 3005-3015.

Salceda, S. and Caro, J. 1997. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. *J. Biol. Chem.* **272**: 22642-22647.

Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., and Howley, P.M. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* **63**: 1129-1136.

Scheffner, M., Nuber, U., and Huibregtse, J.M. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. *Nature* **373**: 81-83.

Semenza, G.L. and Wang, G.L. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol. Cell. Biol.* **12**: 5447 .

Semenza, G.L. 1999. Regulation of mammalian oxygen homeostasis by hypoxia-inducible factor 1. *Annu. Rev. Cell Dev. Biol.* **15**: 551-578.

Shweiki, D., Itin, A., Soffer, D., and Keshet, E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* **359**: 843-845.

Van Meir, E.G., Polverini, P.J., Chazin, V.R., Su Huang, H.-J., de Tribolet, N., and Cavenee, W.K. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. *Nature Genet.* **8**: 171-176.

Wang, G.L. and Semenza, G.L. 1993. Characterization of hypoxia-inducible factor-1 and regulation of DNA binding activity by hypoxia. *J. Biol. Chem.* **268**: 21513-21518.

Wang, G.L., Jiang, B.-H., Rue, E.A., and Semenza, G.L. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc. Natl. Acad. Sci. USA* **92**: 5510-5514.

Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A., and Ferrara, N. 1995. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. *J. Clin. Invest.* **95**: 1789-1797.

Wu, X.W., Bayle, J.H., Olson, D., and Levine, A.J. 1993. The p53 mdm-2 autoregulatory feedback loop. *Genes Dev.* **7**: 1126-1132.

APPENDICES:

Appendix 1:

Reprint of publication: (Page Numbers 16-27)

Ravi, R., Mookerjee, B., Bhujwala, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes & Development* 14:34-44, 2000.

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α

Rajani Ravi,¹ Bijoyesh Mookerjee,¹ Zaver M. Bhujwala,² Carrie Hayes Sutter,³ Dmitri Artemov,² Qinwen Zeng,¹ Larry E. Dillehay,¹ Ashima Madan,⁴ Gregg L. Semenza,³ and Atul Bedi¹

¹Johns Hopkins Oncology Center, ²Department of Radiology, and ³Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287 USA; ⁴Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, 94305 USA

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α

Rajani Ravi,¹ Bijoyesh Mookerjee,¹ Zaver M. Bhujwalla,² Carrie Hayes Sutter,³ Dmitri Artemov,² Qinwen Zeng,¹ Larry E. Dillehay,¹ Ashima Madan,⁴ Gregg L. Semenza,^{3,5} and Atul Bedi¹

¹Johns Hopkins Oncology Center, ²Department of Radiology, and ³Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287 USA; ⁴Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, 94305 USA

The switch to an angiogenic phenotype is a fundamental determinant of neoplastic growth and tumor progression. We demonstrate that homozygous deletion of the *p53* tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice. We find that *p53* promotes Mdm2-mediated ubiquitination and proteasomal degradation of the HIF-1 α subunit of hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that regulates cellular energy metabolism and angiogenesis in response to oxygen deprivation. Loss of *p53* in tumor cells enhances HIF-1 α levels and augments HIF-1-dependent transcriptional activation of the vascular endothelial growth factor (*VEGF*) gene in response to hypoxia. Forced expression of HIF-1 α in *p53*-expressing tumor cells increases hypoxia-induced *VEGF* expression and augments neovascularization and growth of tumor xenografts. These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of *p53* function contributes to the angiogenic switch during tumorigenesis.

[**Key Words:** *p53*; hypoxia-inducible factor-1 (HIF-1); angiogenesis; vascular endothelial growth factor (VEGF); hypoxia; cancer]

Received August 2, 1999; revised version accepted November 19, 1999.

Regions of vascular deficiency or defective microcirculation in growing tumors are deprived of O₂, glucose, and other nutrients. Apoptosis induced by nutrient deficiency counterbalances cell proliferation and limits tumor growth (Holmgren et al. 1995; O'Reilly et al. 1996; Parangi et al. 1996). Clonal evolution of tumor cells in this hypoxic microenvironment results from selection of subpopulations that not only resist apoptosis (Graeber et al. 1996) but also promote the formation of new blood vessels (for review, see Hanahan and Folkman 1996; Folkman 1997). In addition to promoting further growth of the primary tumor, cellular adaptation to hypoxia and tumor neovascularization strongly correlate with the risk of invasion and metastasis (Brown and Giaccia 1998; Dang and Semenza 1999; for review, see Folkman 1997). The switch to an angiogenic phenotype is considered to be a fundamental determinant of neoplastic progression (Gimbrone et al. 1972; Folkman et al. 1989; Bergers et al. 1999). This realization has, in turn, fueled an intense search for the molecular mechanisms by which the angiogenic switch is activated during tumorigenesis.

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factor that regulates O₂ homeostasis and physiologic responses to O₂ deprivation (for review, see Guillemin and Krasnow 1997; Semenza 1999). HIF-1 consists of two subunits, HIF-1 α and HIF-1 β , that belong to a subfamily of basic helix-loop-helix (bHLH) transcription factors containing a PAS (Per-ARNT-Sim) motif (Wang et al. 1995). A decrease in cellular O₂ tension leads to elevation of HIF-1 activity via stabilization of the HIF-1 α protein; conversely, ubiquitin-mediated proteolysis of HIF-1 α on reexposure to a normoxic environment results in rapid decay of HIF-1 activity (Semenza and Wang 1992; Wang et al. 1995; Salceda and Caro 1997; Huang et al. 1998; Kallio et al. 1999). The binding of HIF-1 α , in conjunction with its dimerization partner HIF-1 β , to DNA (consensus binding sequence, 5'-RCGTG-3') leads to the transcriptional activation of genes that mediate anaerobic metabolism (glucose transporters and glycolytic enzymes), O₂-carrying capacity (erythropoietin, transferrin), and vasodilatation (inducible nitric oxide synthase and heme oxygenase-1) (for review, see Guillemin and Krasnow 1997; Semenza 1999). HIF-1 also binds to the 5' flanking sequence of the vascular endothelial growth factor (*VEGF*) gene and is required for transactivation of *VEGF* in response to hypoxia (Forsythe

⁵Corresponding author.
E-MAIL gsemenza@jhmi.edu; FAX (410) 955-0484.

et al. 1996; Carmeliet et al. 1998; Iyer et al. 1998; Ryan et al. 1998). The binding of VEGF to the receptor tyrosine kinases flk1/KDR, flt-1, and flt-4 (VEGFR-1-VEGFR-3) on vascular endothelial cells promotes their proliferation and leads to vessel formation (for review, see Ferrara 1993; Risau and Flamme 1995; Brown et al. 1996). In contrast to wild-type cells, *VEGF* gene expression is not induced by hypoxia in HIF-1 α -deficient embryonic stem cells, and dramatic vascular regression occurs in HIF-1 α -null mouse embryos (Iyer et al. 1998; Kotch et al. 1999). Therefore, HIF-1 is a key transcriptional mediator of metabolic adaptation and VEGF-mediated angiogenesis in response to hypoxia. Although these responses serve to maintain O₂ homeostasis in normal tissues, they are also co-opted by tumors to facilitate neovascularization and growth. Akin to their role in vascular development and remodeling in normal tissues, HIF-1 α (Maxwell et al. 1997; Carmeliet et al. 1998; Ryan et al. 1998) and VEGF (Plate et al. 1992; Shweiki et al. 1992; Kim et al. 1993; Millauer et al. 1994) facilitate tumor angiogenesis, and both HIF-1 α (Zhong et al. 1999) and VEGF (for review, see Folkman 1997) are overexpressed in a wide variety of human cancers.

The genetic alterations that are responsible for oncogenesis and tumor progression may also underlie the ability of tumors to switch to an angiogenic phenotype. The human *p53* tumor suppressor gene encodes a multifunctional transcription factor that mediates cellular responses to diverse stimuli, including DNA damage and hypoxia (for review, see Giaccia and Kastan 1998). In addition to being an integral component of the surveillance mechanisms that arrest cell cycle progression under adverse conditions, p53 is also involved in mediating hypoxia-induced apoptosis (Graeber et al. 1996) and inducing inhibitors of angiogenesis such as thrombospondin-1 (Dameron et al. 1994; Van Meir et al. 1994). Evidence also suggests that p53 negatively regulates *VEGF* expression (Mukhopadhyay et al. 1995; Bouvet et al. 1998; Fontanini et al. 1998). Somatic mutations of the *p53* gene represent one of the most common genetic alterations in human cancers, and the acquisition of such defects is strongly associated with tumor progression and metastasis (for review, see Levine 1997).

In this study, we demonstrate that genetic inactivation of p53 in cancer cells provides a potent stimulus for tumor angiogenesis and identify a novel mechanism by which loss of p53 function contributes to activation of the angiogenic switch in tumors. We find that homozygous deletion of p53 via homologous recombination in human colon cancer cells promotes the neovascularization and growth of tumor xenografts in nude mice. We show that p53 inhibits HIF-1 activity by targeting the HIF-1 α subunit for Mdm2-mediated ubiquitination and proteasomal degradation. Conversely, the loss of p53 enhances hypoxia-induced HIF-1 α levels and augments HIF-1-dependent expression of VEGF in tumor cells. We further demonstrate that forced expression of HIF-1 α in p53-expressing tumor cells promotes *VEGF* expression and neovascularization of tumor xenografts. These findings indicate that inactivation of p53 in tumor cells con-

tributes to activation of the angiogenic switch via amplification of normal HIF-1-dependent responses to hypoxia.

Results

Inhibition of tumor angiogenesis and growth by p53

The effect of p53 on tumor cell growth and angiogenesis was examined by comparing an isogenic set of human colon adenocarcinoma cell lines differing only in their p53 status (Bunz et al. 1998). The parental HCT116 line, containing wild-type p53 (p53^{+/+}), and a p53-deficient derivative (p53^{-/-}), generated by homologous recombination, demonstrated equivalent growth kinetics in tissue culture, with doubling times of 29 and 32 hr, respectively (Fig. 1A). However, xenografts (2.5 \times 10⁴–2.5 \times 10⁵ cells) of p53^{-/-} HCT116 cells in athymic BALB/c (nu/nu) mice exhibited a significantly shorter latency and marked increase in tumor growth kinetics compared with their p53^{+/+} counterparts (Fig. 1B,C). Whereas 12/12 animals inoculated with 2.5 \times 10⁴ p53^{-/-} cells developed tumors within 3 weeks, only 1/12 mice receiving the same number of p53^{+/+} cells was able to establish a tumor during the entire 8-week observation period. To examine whether the observed differences in growth kinetics in vivo were associated with variation in tumor vascularity, tumors established from p53^{+/+} and p53^{-/-} cells were subjected to histologic analysis and nuclear magnetic resonance (NMR) imaging. Immunohistochemical analyses of tumor sections using an antibody against von Willebrand Factor (vWF) demonstrated significantly increased blood vessel density in p53^{-/-} tumors compared with their p53^{+/+} counterparts (Fig. 1D,E). Analyses of neovascularization by NMR imaging showed that compared with p53^{+/+} tumors, p53^{-/-} tumors had a higher vascular volume (14 \pm 2.6 μ l/g vs. 8.4 \pm 2.4 μ l/g in highly permeable regions), as well as a threefold greater vascular permeability (0.4 \pm 0.18 μ l/g/min vs. 0.13 \pm 0.04 μ l/g/min in highly vascular zones) (Fig. 1F). Thus, loss of p53 function has a profound effect on the neovascularization and growth of human colorectal cancer xenografts in nude mice.

Effect of p53 genotype on hypoxia-induced VEGF expression and HIF-1 activity

Hypoxia-induced, HIF-1-mediated expression of VEGF stimulates angiogenesis and vascular permeability in neoplastic tissues (Plate et al. 1992; Shweiki et al. 1992; Forsythe et al. 1996; Maxwell et al. 1997; Carmeliet et al. 1998). p53^{+/+} and p53^{-/-} HCT116 cells were analyzed for expression of VEGF mRNA and protein under tissue culture conditions simulating the hypoxic tumor microenvironment. Following exposure to 1% O₂, p53^{-/-} cells exhibited a greater induction of VEGF mRNA and protein compared with their p53^{+/+} counterparts (Fig. 2A,B). Transcriptional activation of the *VEGF* gene in response to hypoxia is mediated by binding of HIF-1 to a 47-bp




Figure 1. Effect of p53 genotype on tumor growth and angiogenesis. (A) Growth of p53^{+/+} (blue) and p53^{-/-} (red) HCT116 cells cultured in DMEM supplemented with 10% fetal calf serum at 37°C and 95%air/5%CO₂. (B, C) Growth of p53^{+/+} (blue) and p53^{-/-} (red) HCT116 xenografts [2.5×10^4 (▲) or 2.5×10^5 (■) cells] injected subcutaneously into right (p53^{+/+}) or left (p53^{-/-}) hind legs of athymic BALB/c (nu/nu) mice. Values expressed represent mean \pm s.e. of 12 xenografts of each cell type. (D) Histologic analysis of blood vessels in p53^{+/+} and p53^{-/-} HCT116 xenograft tumors by staining with H&E or immunoperoxidase detection of endothelial cells using an anti-vWF antibody ($\times 25$). (E) Quantification of blood vessel density in p53^{+/+} (blue) and p53^{-/-} (red) xenografts. The data represent the mean \pm s.e. of the frequency of vessel hits among 300 random sampling points from each of three tumors of either genotype. (F) Representative NMR analysis of in vivo vascular volume (right) and permeability (left) of p53^{+/+} and p53^{-/-} (bottom) HCT116 xenografts.

hypoxia-response element in the 5' flanking region, and a reporter plasmid containing this sequence (VEGF-p11w) is transactivated by cotransfection of an expression vector encoding HIF-1 α (pCEP4/HIF-1 α) (Forsythe et al. 1996). To examine whether p53 influences HIF-1-mediated transcriptional activation of VEGF, p53^{+/+} and p53^{-/-} cells were cotransfected with the VEGF-p11w reporter and CMV β gal [encoding β -galactosidase (β -gal)]. Analyses of luciferase and β -gal activity in response to hypoxia (1% O₂) revealed a fourfold greater increase in VEGF-p11w transcription (relative to β -gal) in p53^{-/-} cells compared with p53^{+/+} cells (Fig. 2C). These differences were not seen when the reporter contained a 3-bp substitution in the hypoxia response element that eliminated HIF-1 binding (VEGF-p11m), suggesting that HIF-1 was a target for p53-mediated inhibition. Coexpression of pCEP4/HIF-1 α in p53^{+/+} cells increased hypoxia-induced activation of VEGF-p11w to levels that approached the reporter activity exhibited by hypoxic p53^{-/-} cells in the absence of exogenous HIF-1 α (Fig. 2C). Conversely, cotransfection of an expression vector encoding wild-type human p53 into p53^{-/-} cells completely repressed hypoxia-induced VEGF-p11w expression (Fig. 2C). Electrophoretic mobility shift assays demonstrated that hypoxia-induced HIF-1 DNA-binding

activity was reduced in p53^{+/+} cells compared with p53^{-/-} cells (Fig. 2D). The specificity of binding of HIF-1 to DNA was confirmed by competing hypoxia-induced DNA-protein complexes with excess unlabeled wild-type probe but not with an unlabeled mutant probe containing the same 3-bp substitution in the HIF-1 binding site as in reporter VEGF-p11m. Thus, p53 inhibits HIF-1 activity and VEGF expression in response to hypoxia.

Effect of p53 on oxygen-regulated expression and stability of HIF-1 α

Hypoxia-induced HIF-1 DNA-binding and transcriptional activity are dependent on increased levels of HIF-1 α protein and its heterodimerization with HIF-1 β (Wang and Semenza 1993; Wang et al. 1995; Jiang et al. 1996; Huang et al. 1998). To investigate whether p53 influences HIF-1 activity by altering expression of HIF-1 α , the levels of HIF-1 α protein and mRNA were assessed in p53^{+/+} and p53^{-/-} cells exposed to either 20% or 1% O₂. In response to hypoxia, p53^{-/-} HCT116 cells or mouse embryonic fibroblasts (MEFs) expressed higher levels of HIF-1 α protein compared with their p53^{+/+} counterparts (Fig. 3A,B). In contrast to HIF-1 α protein levels, HIF-1 α mRNA was expressed at equivalent levels




Figure 2. Effect of p53 genotype on hypoxia-induced VEGF expression and HIF-1 activity. (A) Northern blot analysis of VEGF mRNA expression in p53^{+/+} and p53^{-/-} HCT116 cells incubated for 16 hr in either 20% or 1% O₂. (B) ELISA of VEGF protein concentration in supernatant medium of p53^{+/+} (blue Δ) or p53^{-/-} (red \blacksquare) HCT116 cells incubated for 16–32 hr in 1% O₂. (C) Hypoxia-induced and HIF-1-dependent activation of VEGF-reporter activity in p53^{+/+} (shaded bars) and p53^{-/-} (solid bars) HCT116 cells. Wild-type (p11w) and mutant (p11m) copies of the hypoxia response element from the VEGF gene were inserted 5' to a SV40 promoter-luciferase transcription unit. Cells were cotransfected with either VEGF-p11w or VEGF-p11m and CMV β gal, with or without pCEP4/HIF-1 α or pCMV-p53, exposed to 1% O₂ for 20 hr, and harvested for luciferase assays. The data represent the mean \pm S.E. luciferase activity (normalized for β -gal activity) from three independent experiments. (D) Electrophoretic mobility shift assays of HIF-1 DNA-binding activity in nuclear extracts from p53^{+/+} and p53^{-/-} HCT116 cells exposed to 20% (lanes 1 and 3) or 1% (lanes 2 and 4–6) O₂. HIF-1 DNA binding was confirmed by competition assays using either unlabeled wild-type oligonucleotide (W) or a mutant oligonucleotide (M) containing the same 3-bp substitution as in p11m. Complexes containing HIF-1, constitutive (C), and non-specific (NS) DNA-binding activities [Semenza and Wang 1992] are indicated.

in hypoxic p53^{+/+} and p53^{-/-} cells (Fig. 3C), suggesting an effect of p53 on HIF-1 α protein expression. To confirm this effect, p53^{-/-} cells were cotransfected with pCEP4-HIF-1 α and either pCMV-p53 (encoding wild-type human p53) or empty vector (pCMV0) and exposed to 1% O₂ for 8 hr. Immunoblot analysis showed that p53^{-/-} cells cotransfected with pCMV-p53 exhibited reduced levels of HIF-1 α compared with cells receiving the control vector (Fig. 3D).

The steady state level of HIF-1 α protein is regulated by an oxygen-dependent and iron-sensitive mechanism of ubiquitin-mediated proteasomal degradation [Salceda and Caro 1997; Huang et al. 1998; Kallio et al. 1999]. The 20S proteasome is the core catalytic subunit of the 26S proteasome complex that mediates degradation of ubiquitin-tagged proteins [for review, see Hershko and Ciechanover 1998]. HIF-1 α expression is induced by exposure to hypoxia or treatment with cobalt chloride

(Wang et al. 1995). To examine whether p53 influences the stability of HIF-1 α protein, HIF-1 α expression was analyzed in lysates of cobalt-treated p53^{+/+} and p53^{-/-} cells at serial time intervals following addition of cycloheximide. HIF-1 α protein decayed with a half-life of <20 min in p53^{+/+} cells, compared with >40 min in p53^{-/-} cells (Fig. 3E).

HPV-E6 augments HIF-1 α stability and VEGF expression in response to hypoxia

The human papilloma virus (HPV16) E6 oncoprotein promotes ubiquitin-dependent conjugation and degradation of p53 [Scheffner et al. 1990]. To investigate whether E6-induced degradation of endogenous p53 promotes expression of HIF-1 α and induction of VEGF, the PA-1 ovarian teratocarcinoma cell line was stably transfected with an expression vector encoding HPV-16 E6 (PA-1 E6) or empty vector (PA-1 Neo) [Ravi et al. 1998]. Under hypoxic conditions, PA-1 E6 cells expressed higher levels of HIF-1 α protein compared with PA-1 Neo cells (Fig. 4A). Analyses of HIF-1 α protein stability in cycloheximide-treated cells showed that HIF-1 α protein decayed with a half-life of ~15 min in PA-1 cells, compared with >30 min in PA-1 E6 cells (Fig. 4B). PA-1 Neo or PA-1 E6 cells were cotransfected with either VEGF-p11w or VEGF-p11m reporter and CMV β gal. Analyses of luciferase and β -gal activity in response to hypoxia (1% O₂) revealed a twofold greater increase in VEGF-p11w transcription (relative to β -gal) in PA-1 E6 cells compared




Figure 3. Effect of p53 on oxygen-regulated expression and stability of HIF-1 α . (A) Immunoblot analysis of HIF-1 α expression in p53^{+/+} and p53^{-/-} HCT116 cells cultured for 8 hr in 20% or 1% O₂. The blot was analyzed sequentially with monoclonal antibodies against HIF-1 α (H1 α 67), p53 (DO-1), and β -actin. (B) Immunoblot analysis of HIF-1 α expression in p53^{+/+} and p53^{-/-} MEFs cultured for 8 hr in 20% or 1% O₂. (C) Northern blot analysis of HIF-1 α mRNA expression in p53^{+/+} and p53^{-/-} HCT116 cells cultured as in A. (D) Immunoblot analysis of HIF-1 α protein in p53^{-/-} HCT116 cells cultured in 1% O₂ for 8 hr following cotransfection with pCEP4-HIF-1 α and either pCMV-p53 or empty vector. The blot was analyzed sequentially with anti-HIF-1 α and anti-p53 monoclonal antibodies. (E) Half-life of HIF-1 α protein in p53^{+/+} and p53^{-/-} cells exposed to 100 μ M cobalt chloride following addition of 100 μ M cycloheximide. Lysates of cells harvested at the indicated time intervals were subject to immunoblot analysis of HIF-1 α and p53 expression.




Figure 4. HPV E6 increases expression of HIF-1 α and VEGF in response to hypoxia. (A) Immunoblot analysis of HIF-1 α expression in PA-1 Neo or PA-1 E6 cells cultured for 8 hr in 20% or 1% O₂. (B) Half-life of HIF-1 α protein in PA-1 Neo or PA-1 E6 cells exposed to 100 μ M cobalt chloride following addition of 100 μ M cycloheximide. Lysates of cells harvested at the indicated time intervals were subject to immunoblot analysis of HIF-1 α expression. (C) Hypoxia-induced and HIF-1-dependent activation of VEGF-reporter activity in PA-1 Neo (open bars) and PA-1 E6 (solid bars) cells. Cells were cotransfected with either VEGF-p11w or VEGF-p11m and CMV β gal, exposed to 1% O₂ for 20 hr, and harvested for luciferase assays. The data represent the mean luciferase activity (normalized for β -gal activity) from three independent experiments. (D) ELISA of VEGF protein concentration in supernatant medium of PA-1 Neo (open bar) or PA-1 E6 (solid bar) cells incubated for 16 hr in 1% O₂.

with PA-1 Neo cells (Fig. 4C). Neither cell line exhibited significant transcription of the VEGF-p11m reporter. Consistent with the promotion of HIF-1-dependent VEGF transcription by E6 expression, exposure to 1% O₂ resulted in greater induction of VEGF protein expression in PA-1 E6 cells compared with PA-1 Neo cells (Fig. 4D).

p53 promotes ubiquitin-dependent of HIF-1 α

To determine whether p53 interacts with HIF-1 α in HCT116 cells, as previously demonstrated in MCF-7 cells [An et al. 1998], protein lysates from hypoxic p53^{+/+} and p53^{-/-} cells were immunoprecipitated with an anti-p53 or isotype control antibody, and the resulting immune complexes were subjected to immunoblot assays using an antibody against HIF-1 α . HIF-1 α was detected in immunoprecipitates derived from p53^{+/+} cells but not p53^{-/-} cells or immune complexes precipitated with the control antibody (Fig. 5A).

To determine whether p53 promotes ubiquitination of HIF-1 α , p53^{+/+} and p53^{-/-} cells were cotransfected with an HIF-1 α expression vector (pCEP4/HIF-1 α) and a vector encoding hexahistidine-tagged ubiquitin (His₆-Ub) or the empty control vectors. Transfected cells were exposed to 1% O₂ for 4 hr in the presence of MG132, a peptide aldehyde inhibitor of the 20S proteasome. Aliquots of whole-cell extracts or His-tagged proteins isolated by affinity purification from cell lysates were subjected to immunoblot assays using an anti-HIF-1 α monoclonal antibody (Fig. 5B). Immunoblot analysis of whole cell extracts of p53^{+/+} cells detected a 120-kD protein corresponding to the apparent molecular mass of HIF-1 α (Wang et al. 1995), as well as an additional series of slower migrating complexes. The higher molecular weight complexes represented polyubiquitinated forms

of HIF-1 α as they were also detected by immunoblot analysis of His-tagged proteins with an anti-HIF-1 α monoclonal antibody. Compared with p53^{+/+} cells, p53^{-/-} cells transfected with vectors encoding HIF-1 α and His₆-Ub demonstrated a higher level of unconjugated HIF-1 α and a reciprocal reduction in polyubiquitinated HIF-1 α (Fig. 5B). Introduction of a p53 expression vector (pCMV-p53) into p53^{-/-} cells increased the proportion of HIF-1 α that was ubiquitinated under hypoxic conditions (Fig. 5B).

Conjugation of Ub to proteins destined for degradation involves conversion of Ub to a high-energy thiol ester by the E1 Ub-activating enzyme followed by the transfer of activated Ub to the substrate via the activity of an E2 Ub-conjugating enzyme and an E3 Ub-protein ligase [for review, see Hershko and Ciechanover 1998]. To confirm the requirement of the Ub-proteasome system for p53-mediated degradation of HIF-1 α , we examined the effect of p53 on hypoxia-induced HIF-1 α expression in the BALB/c 3T3-derived ts20TG^R cell line, which harbors a thermolabile E1, or a derivative cell line (H38-5), in which the temperature-sensitive defect was corrected by introduction of the human E1 cDNA [Chowdary et al. 1994]. ts20TG^R and H38-5 cells were transfected with either an expression vector encoding human p53 or a control vector and transferred to hypoxic chambers (1% O₂) at either the permissive temperature (35°C) or the restrictive temperature (39°C). Transfection of p53 into ts20TG^R cells resulted in reduced HIF-1 α levels at 35°C but not at 39°C (Fig. 5C). However, E1-expressing H38-5 cells exhibited p53-mediated reduction of HIF-1 α levels at both temperatures. Taken together, the data indicate that p53 limits hypoxia-induced expression of HIF-1 α by promoting its ubiquitination and proteasomal degradation.

Whereas a single E1 is responsible for activation of ubiquitin, multiple E3 enzymes are responsible for specific selection of proteins destined for degradation. Because p53 induces the Mdm2 E3 Ub-protein ligase and is itself a target for Ub-mediated degradation via its interaction with Mdm2 [Momand et al. 1992; Barak et al. 1993; Wu et al. 1993; Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997], this raised the possibility that HIF-1 α is recruited to Mdm2 via its interaction with p53. To test this hypothesis, protein lysates of p53^{-/-} HCT116 cells that were transfected with either pCMV-p53 or empty vector and transferred to 1% O₂ for 6 hr were immunoprecipitated with anti-Mdm2 or isotype control antibody, and the resulting immune complexes were subjected to immunoblot assays using an antibody against HIF-1 α . Anti-Mdm2 immunoprecipitates derived from cells transfected with p53 displayed significantly higher levels of coprecipitated HIF-1 α protein compared to immune complexes derived from p53^{-/-} HCT116 cells with the empty vector (Fig. 5D).

Amino acid residues Phe-19, Leu-22, and Trp-23 in the amino-terminal transactivation domain of p53 are critical for its interaction with Mdm2 [Lin et al. 1994]. A p53 double mutant at residues 22 and 23 (p53 Gln22, Ser23) fails to interact with Mdm2 and is also transactivation




Figure 5. Effect of p53 expression on ubiquitin-mediated degradation of HIF-1 α . (A) Interaction of p53 with HIF-1 α . Lysates of p53 $+/+$ or p53 $-/-$ HCT116 cells exposed to 1% O₂ for 8 hr were immunoprecipitated with either anti-p53 antibody or isotype control antibody (C) and the resultant immune complexes were subjected to immunoblot analysis with anti-HIF-1 α monoclonal antibody. (B) Differential ubiquitination of HIF-1 α in hypoxic p53 $+/+$ and p53 $-/-$ HCT116 cells. Cells were cotransfected with pCMV β gal and pCEP4/HIF-1 α with either MT107/His₆-Ub or empty vector (MT107), and cultured in 1% O₂ for 4 hr in the presence of 50 μ M MG132. Aliquots of whole-cell extract (WCE) or His-tagged proteins purified from whole-cell lysates (His-Ub) were subjected to immunoblot analysis with anti-HIF-1 α or anti-HIF-1 β antibody. (C) Effect of p53 expression on HIF-1 α protein levels in hypoxic ts20TGR and H38-5 cells. Cells transfected with pCMV-p53 or pCMV β gal were maintained at either 35°C or 39°C for 8 hr and exposed to 1% O₂ for an additional 8 hr at their respective temperatures. Whole-cell lysates were subjected to immunoblot analysis with anti-HIF-1 α or anti-p53 antibodies. (D) Effect of p53 on complex formation between HIF-1 α and Mdm2. Lysates of p53 $-/-$ HCT116 cells transfected with either pCMV-p53 or empty vector and transferred to 1% O₂ for 6 hr were immunoprecipitated with anti-Mdm2 or isotype control antibody, and the resulting immune complexes were subjected to immunoblot assays using an antibody against HIF-1 α . (E) Effect of wild-type p53, p53 Δ I, or p53Gln22,Ser23 on expression of HIF-1 α in response to hypoxia. p53 $-/-$ HCT116 cells transfected with pCMV β gal and either pCMV-p53, pCB6 + p53 Δ I, pCMV-p53Gln22,Ser23, or empty vector were exposed to 1% O₂ for 8 hr. Whole-cell lysates were subjected to immunoblot analysis with anti-HIF-1 α or anti-Mdm2 antibodies. (F) Effect of dominant-negative (RING finger) mutants of Mdm2 on hypoxia-induced expression of HIF-1 α . p53 $+/+$ and p53 $-/-$ HCT116 cells transfected with vectors encoding human Mdm2 (1-440) (pCHDM1-440), Mdm2 (464Ala) (pCHDM464Ala), or pCMV β gal were exposed to 1% O₂ for 8 hr. Whole-cell lysates were subjected to immunoblot analysis with anti-HIF-1 α , anti-p53, or anti-Mdm2 antibodies. (G) Effect of dominant-negative (RING finger deletion mutant) Mdm2 on p53-mediated inhibition of HIF-1 α expression in ts20TGR and H38-5 cells. Cells cotransfected with pCMV-p53 and either pCHDM1-440 or empty vector were maintained at 39°C for 12 hr and then exposed to 20% or 1% O₂ for an additional 8 hr at 39°C. Whole-cell lysates were subjected to anti-HIF-1 α immunoblot analysis.

deficient (Lin et al. 1994). A p53 mutant carrying a deletion of residues 13-19 (p53 Δ I) is also unable to bind to Mdm2 but retains its transactivation function (Marston et al. 1995). To investigate whether p53 requires interaction with Mdm2 to mediate degradation of HIF-1 α , p53 $-/-$ HCT116 cells were transfected with encoding either wt p53, p53 22-23, p53 Δ I, or control vector and analyzed for HIF-1 α expression under hypoxic conditions. In contrast to wild-type p53, the p53 mutants (p53 Δ I or p53 Gln22, Ser23) or the control vector were unable to reduce the levels of HIF-1 α (Fig. 5E).

The Ub-protein ligase function of Mdm2 is dependent on a RING finger domain (residues 434-490) at the carboxyl terminus (Honda et al. 1997). Mdm2 mutants with a deletion of the RING finger domain [Mdm2 (1-440)] or a substitution of a cysteine residue at position 464 to alanine [Mdm2 (464Ala)] are deficient in Ub-protein ligase function but retain the ability to bind p53, thereby

behaving in a dominant negative manner (Kubbutat et al. 1999). Introduction of Mdm2 (1-440) or Mdm2 (464Ala) augmented hypoxia-induced HIF-1 α levels in p53 $+/+$ HCT116 cells but did not significantly influence HIF-1 α expression in hypoxic p53 $-/-$ HCT116 cells (Fig. 5F). To determine whether Mdm2 functions as an E3-ligase that mediates p53-induced degradation of HIF-1 α , ts20TGR and H38-5 cells were cotransfected with expression vectors encoding wild-type p53 and either Mdm2 (1-440) or empty control vector and transferred to hypoxic chambers (1% O₂) at 39°C. Cotransfection of Mdm2 (1-440) increased hypoxia-induced HIF-1 α expression in E1-proficient H38-5 cells coexpressing p53 to levels observed in E1-deficient ts20TGR cells (Fig. 5G). Together, the data in Figure 5 are consistent with a model in which p53 acts as a molecular chaperone that facilitates recognition and recruitment of HIF-1 α for ubiquitination by Mdm2.

Enhancement of tumor angiogenesis in $p53^{+/-}$ cells by forced expression of HIF-1 α

To determine whether p53-mediated degradation of HIF-1 α contributes to the suppression of tumor angiogenesis and growth, $p53^{+/-}$ HCT116 cells were stably transfected with pCEP4/HIF-1 α (HCT116-HIF-1 α) (Fig. 6A). Under hypoxic conditions, stable transfectants overexpressing HIF-1 α demonstrated significantly increased VEGF mRNA levels compared with the parental $p53^{+/-}$ cells (Fig. 6B). When inoculated into athymic nude mice, HCT116-HIF-1 α cells established tumors with a shorter latency and exhibited a significant increase in tumor growth kinetics compared with the parental cells (Fig. 6C). Histologic evaluation and analyses of NMR maps, as described earlier, revealed a significant increase in blood vessel density, vascular volume (17.4 μ l/g) and , (0.8 μ l/g/min) in xenografts established from HCT116-HIF-1 α cells compared with those derived from the parental $p53^{+/-}$ HCT116 cells (Fig. 6D).


Discussion

Recognition of the importance of angiogenesis for the growth and metastasis of cancers has raised fundamental questions regarding the molecular mechanisms of the angiogenic switch during tumor progression. The genetic alterations involved in tumorigenesis are also responsible for the phenotypic characteristics of cancer cells. The p53 tumor suppressor gene is one of the most frequently mutated genes in human cancers (for review, see Levine 1997). In addition to p53 mutations, which occur in ~50% of all cancers (involving >50 tissue types), p53 is also inactivated by viral oncoproteins such as the E6 protein of cervical cancer-associated HPV 16 and 18, adenovirus E1A, and SV40 large T antigen (for review, see Levine 1997). Our observations indicate that loss of p53 function, via somatic mutations or expression of viral oncoproteins, contributes to activation of the angiogenic switch during tumorigenesis.

In addition to identifying the loss of p53 as a discrete and potentially rate-limiting event in tumor angiogenesis, we define a novel mechanism by which p53 regulates the angiogenic switch. Our observations indicate that p53 inhibits hypoxia-induced expression of HIF-1 α by facilitating its ubiquitination and subsequent degradation. This mechanism is distinct from the proposal that p53 inhibits HIF-1-mediated transactivation by competing for the p300 coactivator (Blagosklonny et al. 1998) and is analogous to the proposed role of the von Hippel-Lindau (VHL) tumor suppressor (Maxwell et al. 1999). As in the case of VHL (Maxwell et al. 1999), we demonstrate that p53 interacts with HIF-1 α in vivo, as reported previously (An et al. 1998). In addition, we demonstrate for the first time that a tumor suppressor (p53) promotes the ubiquitin-mediated degradation of HIF-1 α via recruitment of an E3 ubiquitin-protein ligase (Mdm2). Although ubiquitination is assumed to be the mechanism by which VHL affects HIF-1 α degradation, our data provide the first direct evidence for this mechanism of tumor suppressor action. The constitutive stabilization of HIF-1 α and the related HIF-2 α protein) resulting from VHL loss of function may underlie the predisposition to highly angiogenic tumors in VHL disease, a rare hereditary cancer syndrome. Our findings indicate that deregulation of HIF-1 α expression, leading to overexpression of VEGF, may contribute to the angiogenic switch conferred by inactivation of p53 in a broad array of human cancers. In accordance with this hypothesis, HIF-1 α is frequently overexpressed in common human cancers and there is a statistically significant correlation between the presence of mutant p53 and HIF-1 α overexpression (Zhong et al. 1999). Our findings suggest that increased HIF-1 activity resulting from loss of p53 function may contribute to the overexpression of VEGF that is observed in a wide variety of human cancers (for review, see Brown et al. 1996; Folkman 1997).

The angiogenic switch is regulated by changes in the relative balance between inducers and inhibitors of en-

Figure 6. Increased tumor angiogenesis and growth in $p53^{+/-}$ cells with forced overexpression of HIF-1 α . (A) Immunoblot analyses of HIF-1 α protein levels in $p53^{+/-}$ HCT116 cells and $p53^{+/-}$ HCT116 cells stably transfected with a HIF-1 α expression vector (HCT116-HIF-1 α) following exposure to 1% O_2 for 8 hr. (B) Northern blot analysis of VEGF mRNA levels in $p53^{+/-}$ HCT116 and HCT116-HIF-1 α cells cultured for 16 hr in 20% or 1% O_2 . (C) Growth of $p53^{+/-}$ HCT116 (blue ■) and HCT116-HIF-1 α (red ▲) cells (2.5×10^6) injected subcutaneously into the flanks of athymic BALB/c nude mice. Values expressed represent mean \pm S.E. of 12 xenografts of each cell type. (D) Quantification of vascular volume, permeability, and blood vessel density in $p53^{+/-}$ HCT116 (shaded bars) and HCT116-HIF-1 α (solid bars) xenograft tumors. In vivo vascular volume and permeability of the tumors were determined by NMR analyses, and blood vessel frequency in stained sections of excised tumors was analyzed as described in Fig. 1.



endothelial cell proliferation and migration (for review, see Hanahan and Folkman 1996). The switch can be activated by increasing the levels of inducers, such as VEGF, and/or by reducing the concentration of inhibitors, such as thrombospondin-1 (TSP-1). The p53-mediated inhibition of VEGF expression demonstrated in this study, together with the previously reported ability of p53 to up-regulate TSP-1 (Dameron et al. 1994), indicates that p53 provides dual functions that regulate angiogenesis. Thus, the loss of p53 function during tumorigenesis deregulates both arms of the balance, providing a potent stimulus for neovascularization and tumor progression.

In addition to loss-of-function mutations in tumor suppressor genes such as *p53* or *VHL*, oncogene activation is also capable of stimulating HIF-1 activity. Expression of the *v-Src* oncogene induces expression of HIF-1 α protein, HIF-1 DNA-binding activity, and transcriptional activation of *VEGF* and *enolase 1* (Jiang et al. 1997). A phosphatidylinositol 3-kinase/Akt pathway of HIF-1 activation may induce *VEGF* expression in *Ha-ras*-transformed cells (Mazure et al. 1997). Therefore, increased HIF-1 expression is associated with multiple genetic alterations that promote tumor angiogenesis. Because HIF-1 is also a key transcriptional activator of genes encoding glucose transporters and glycolytic enzymes (Iyer et al. 1998), these genetic alterations also contribute to the metabolic adaptation and enhanced survival of tumor cells in hypoxic microenvironments.

As p53 is an important mediator of DNA damage-induced apoptosis, the angiogenic phenotype conferred by inactivation of p53 in human cancers is frequently associated with resistance to conventional genotoxic anticancer agents (for review, see Lowe 1995). Because p53-deficient tumors remain dependent on angiogenesis for growth and metastasis, inhibition of angiogenesis may represent an effective therapeutic intervention (Boehm et al. 1997; Bergers et al. 1999). Recent studies indicate that inhibition of tumor-derived VEGF expression restricts angiogenesis and promotes vascular regression in experimental tumor models (Kim et al. 1993; Millauer et al. 1994, 1996; Warren et al. 1995; Goldman et al. 1998). Loss of HIF-1 activity is also associated with decreased angiogenesis and growth of tumor xenografts in nude mice (Jiang et al. 1997; Maxwell et al. 1997; Carmeliet et al. 1998; Ryan et al. 1998). By demonstrating that deregulation of HIF-1 underlies the increased expression of VEGF in p53-deficient cancers, our data provide further support for the hypothesis that inhibition of HIF-1 may abrogate the ability of such tumors to establish an adequate vascular supply and adapt their cellular metabolism to hypoxia, thereby curtailing their growth and metastasis.

Materials and methods

Cell lines and culture

The parental HCT116 human colon adenocarcinoma cell line, containing wild-type p53 (p53^{+/+}), and a p53-deficient derivative (p53^{-/-}) created by homozygous deletion via homologous re-

combination (Bunz et al. 1998), were a gift from Bert Vogelstein. p53^{+/+} HCT116 cells were transfected with pCEP4/HIF-1 α and a pool of stable transformants overexpressing HIF-1 α (HCT116-HIF-1 α) was selected in the presence of hygromycin (200 μ g/ml). p53^{+/+} or p53^{-/-} HCT116 and HCT116-HIF-1 α cells were maintained in McCoy's modified medium (Life Technologies, Inc.) supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml), and streptomycin (100 μ g/ml) at 37°C and 5% CO₂. PA-1 ovarian teratocarcinoma cells stably transfected with pCMV-HPV16 E6 or pCMV-Neo, generated as described (Ravi et al. 1998), were maintained in Basal Eagle medium supplemented with 0.5 mg/ml G418, 10% FCS, and antibiotics (as described above) at 37°C and 5% CO₂. p53^{+/+} and p53^{-/-} MEFs (gift from Tyler Jacks, Massachusetts Institute of Technology, Cambridge, MA), were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS and antibiotics. The BALB/c 3T3-derived ts20TG^R or H38-5 cell lines (Chowdary et al. 1994) (gift from Harvey L. Ozer) were maintained at 35°C in DMEM supplemented with 10% fetal bovine serum and antibiotics. The permissive and nonpermissive temperatures for the ts20TG^R E1-mutant cell line are 35°C and 39°C, respectively. Cells were plated on 100-mm petri dishes and allowed to approach confluence. For hypoxic conditions, cells were placed in a modular incubator chamber and flushed with a gas mixture containing 1% O₂, 5% CO₂, and balance N₂ (Semenza and Wang 1992).

Growth of tumor xenografts in nude mice

HCT116 cells (2.5×10^4 , 2.5×10^5 , or 2.5×10^6) suspended in 0.1 ml of PBS were injected subcutaneously into the right (p53^{+/+}) or left (p53^{-/-}) hind legs or flanks of athymic BALB/c (nu/nu) mice. Tumor volumes were determined by external measurement in three dimensions using the equation $V = [L \times W \times H] \times \pi / 6$, where V = volume, L = length, W = width, and H = height. Care of experimental animals was in accordance with institutional animal care and use committee guidelines.

NMR analyses of in vivo vascular volume and permeability of tumor xenografts

Multislice maps of relaxation rates (T_1^{-1}) were obtained by a saturation recovery T_1 SNAPSHOT-FLASH imaging method (flip angle of 5°, echo time of 2 msec). Images of four slices (slice thickness of 1 mm) acquired with an in-plane spatial resolution of 125 μ m (128×128 matrix, 16-mm field of view, NS = 8) were obtained for three relaxation delays (100 msec, 500 msec, and 1 sec) for each of the slices; $128 \times 128 \times 4$ T_1 maps were acquired within 7 min. An M_0 map with a recovery delay of 7 sec was acquired once at the beginning of the experiment. Images were obtained before intravenous administration of 0.2 ml of 60 mg/ml albumin-GdDTPA in saline (dose of 500 mg/kg) and repeated starting after the injection up to 32 min. Relaxation maps were reconstructed from data sets for three different relaxation times and the M_0 data set on a pixel by pixel basis. At the end of the imaging studies, the animal was sacrificed, and 0.5 ml of blood was withdrawn from the inferior vena cava. Vascular volume and permeability product surface area (PS) maps were generated from the ratio of $\Delta(1/T_1)$ values in the images to that of blood. The slope of $\Delta(1/T_1)$ ratios versus time in each pixel was used to compute PS, whereas the intercept of the line at zero time was used to compute vascular volume. Thus, vascular volumes were corrected for permeability of the vessels. Volume and permeability values (mean \pm S.E.) were computed for tumor xenografts established with HCT116

p53^{+/+} (n = 4), HCT116 p53^{-/-} (n = 5), and HCT116-HIF-1 α (n = 2) cells.

Histologic analyses of blood vessel density in tumor xenografts

Five-micrometer sections prepared from paraffin-embedded tissue were stained with hematoxylin & eosin (H & E) and subjected to immunoperoxidase detection of endothelial cells using an anti-vWF antibody. A circular matrix of 25 random sampling points (per unit area) was superimposed on defined fields, and the points overlying a vessel were scored as a percentage of the total points.

Plasmids

Plasmids encoding human wild-type full-length p53 (pC53-SN; gift from Bert Vogelstein, Johns Hopkins Oncology Center, Baltimore, MD), mutant p53 (pCB6+ p53 Δ I) (Marston et al. 1994), p53 double mutants (pCMV-p53Gln22, Ser23) (Lin et al. 1994), human mutant Mdm2 (pCHDM1-440 and pCHD464Ala; provided by Karen Vousden) (Kubbutat et al. 1999), His₆-Ubiquitin (MT107-His₆-Ub; provided by Dirk Bohmann) (Musti et al. 1997), pCMV-HPV16 E6 (provided by Kathy Cho, Johns Hopkins University School of Medicine, Baltimore, MD), and HIF-1 α (pCEP4-HIF-1 α) (Forsythe et al. 1996; Jiang et al. 1996) have been described previously.

Analysis of VEGF reporter activity

Wild-type (p11w) and mutant (p11m) copies of the hypoxia response element from the VEGF gene cloned 5' to a SV40-promoter-luciferase transcription unit were described previously (Forsythe et al. 1996). p53^{+/+} or p53^{-/-} HCT116 cells and PA-1 Neo or PA-1 E6 cells were cotransfected (using Lipofectin) with either VEGF-p11w or VEGF-p11m and CMV β gal, with or without pCEP4/HIF-1 α . Transfected cells were exposed to hypoxia (1% O₂) for 20 hr and harvested for β -gal and luciferase assays (Promega) in fixed protein aliquots. Luciferase activity was normalized for β -gal activity. The data represent the mean \pm S.E. from three independent experiments.

Electrophoretic mobility shift assays of HIF-1 DNA-binding activity

Nuclear extracts (5 μ g) prepared from p53^{+/+} and p53^{-/-} HCT116 cells exposed to either 20% or 1% O₂ were incubated with ³²P-labeled double-stranded oligonucleotide probe containing a wild-type HIF-1 binding site and DNA/protein complexes were analyzed by polyacrylamide gel electrophoresis as described previously (Semenza and Wang 1992; Jiang et al. 1996). HIF-1 binding to the probe was confirmed by competition assays using 50 ng of either unlabeled wild-type oligonucleotide or a mutant oligonucleotide containing the same 3-bp substitution as in p11m (Semenza and Wang 1992; Forsythe et al. 1996).

Northern blot

VEGF and HIF-1 α mRNA was assessed by Northern blot analyses of total RNA prepared from p53^{+/+} or p53^{-/-} HCT116 and HCT116-HIF-1 α cells cultured for 16 hr in either 20% or 1% O₂. Total RNA (20- μ g aliquots) was fractionated by 1.2% agarose-formaldehyde gel electrophoresis and transferred to nylon membranes. The blots were hybridized to probes for VEGF, HIF-1 α , and β -actin mRNA using random primer labeling (Boehringer Mannheim) (Jiang et al. 1997).

ELISA

Quantikine (R & D Systems) was used to measure VEGF protein in supernatant medium of p53^{+/+} or p53^{-/-} HCT116 cells and PA-1 Neo or PA-1 E6 cells cultured as described above for 16–32 hr.

Immunoblot analyses and immunoprecipitation

Nuclear extracts or whole-cell lysates were prepared, fractionated by SDS-PAGE, transferred to PVDF membranes (Millipore, Bedford, MA), and immunoblotted with monoclonal antibodies against HIF-1 α (H1 α 67; Novus Biologicals, Inc.) (Zhong et al. 1999), p53 (DO-1, Ab-6; Oncogene Research Products), Mdm2 (Ab-1; Oncogene Research Products), or β -actin (Santa Cruz Biotechnology, Inc.). Immunoreactive proteins were detected using enhanced chemiluminescence (Amersham). For analysis of protein interactions, whole-cell lysates were immunoprecipitated with antibodies against either p53 or Mdm2 or isotype control antibody, and the resultant immune complexes were subjected to immunoblot analysis with anti-HIF-1 α monoclonal antibody H1 α 67.

Analysis of HIF-1 α protein half-life and ubiquitin-dependent degradation

Cells exposed to 100 μ M cobalt chloride for 4 hr were treated with 100 μ M cycloheximide. Whole-cell extracts were prepared at intervals of 15–40 min and subjected to immunoblot analyses with anti-HIF-1 α antibody. To assess ubiquitination of HIF-1 α in hypoxic conditions, p53^{+/+} and p53^{-/-} HCT116 cells were cotransfected (Lipofectin, Life Technologies, Inc.; 100-mm dishes) with 2 μ g of pCMV β gal and 6 μ g each of pCEP4/HIF-1 α and either MT107/His₆-Ub or empty vector (MT107) (Musti et al. 1997), and cultured in 1% O₂ for 4 hr in the presence of 50 μ M MG132 (Peptides International, Inc.). Cells were lysed in buffer supplemented with 5 mM N-ethylmaleimide and 50 mM imidazole, as described (Ravi et al. 1998). Whole-cell extracts or His-tagged proteins [purified from 500 μ g of whole cell-protein lysates (normalized to β -gal activity) using Talon Metal Affinity Resin (Clontech)] were subjected to SDS-PAGE and immunoblot analysis with anti-HIF-1 α antibody. To analyze whether the effect of p53 on HIF-1 α protein levels was dependent on ubiquitination, ts20TG^R and H38-5 cells were transfected (using Lipofectin) with pCMV-p53 and pCMV β gal, maintained at either 35°C or 39°C for 8 hr, and then exposed to 1% O₂ for an additional 8 hr at their respective temperatures. Whole-cell lysates were subjected to immunoblot analysis with anti-HIF-1 α or anti-p53 antibodies.

Acknowledgments

This work was funded in part by grants from the National Institutes of Health (CA71660-01A1 to A.B., RO1-HL55338 to G.L.S., and RO1-CA73850 to Z.M.B.), U.S. Army Medical Research and Materiel Command Department of Defense (DAMD 17-99-1-9230 to A.B.), and the American Cancer Society. A.B. is a recipient of a Passano Physician Scientist award and a Scholar award from the Valvano Foundation for Cancer Research. We thank Dr. Bert Vogelstein for his gift of p53^{+/+} and p53^{-/-} HCT116 cell lines, and the vector encoding wild type p53; Dr. Tyler Jacks for his gift of p53^{+/+} and p53^{-/-} MEFs; Drs. Karen H. Vousden and Arnold J. Levine for vectors encoding mutant p53 and mutant Mdm2; Dr. Harvey L. Ozer for his gift of the ts20TG^R and H38-5 cell lines; Dr. Kathy Cho for her gift of the

vector encoding HPV-16 E6; and Dr. Dirk Bohmann for providing plasmids MT107 and MT123.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- An, W.G., M. Kanekal, M.C. Simon, E. Maltepe, M.V. Blagosklonny, and L.M. Neckers. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1 α . *Nature* **392**: 405–408.
- Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm-2 expression is induced by wild type p53 activity. *EMBO J.* **12**: 461–468.
- Bergers, G., K. Javaherian, K.N. Lo, J. Folkman, and D. Hanahan. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science* **284**: 808–812.
- Blagosklonny, M.V., W.G. An, L.Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. *J. Biol. Chem.* **273**: 11995–11998.
- Boehm, T., J. Folkman, T. Browder, and M.S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. *Nature* **390**: 404–407.
- Bouvet, M., L.M. Ellis, M. Nishizaki, T. Fujiwara, W. Liu, C.D. Bucana, B. Fang, J.J. Lee, and J.A. Roth. 1998. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. *Cancer Res.* **58**: 2288–2292.
- Brown, J.M. and A.J. Giaccia. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. *Cancer Res.* **58**: 1408–1416.
- Brown, L.F., M. Detmar, K. Claffey, J.A. Nagy, D. Feng, A.M. Dvorak, and H.F. Dvorak. 1996. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. In *Control of angiogenesis* (ed. I.D. Goldberg and E. Rosen). Birkhauser Verlag, Berlin, Germany.
- Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J.P. Brown, J.M. Sedivy, K.W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* **282**: 1497–1501.
- Carmeliet, P., Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell et al. 1998. Role of HIF-1 α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* **394**: 485–490.
- Chowdary, D.R., J.J. Dermody, K.K. Jha, and H.L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. *Mol. Cell. Biol.* **14**: 1997–2003.
- Dameron, K.M., O.V. Volpert, M.A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* **265**: 1582–1584.
- Dang, C.V. and G.L. Semenza. 1999. Oncogenic alterations of metabolism. *Trends Biochem. Sci.* **24**: 68–72.
- Ferrara, N. 1993. Vascular endothelial growth factor. *Trends Cardiovasc. Med.* **3**: 244–250.
- Folkman, J. 1997. Tumor angiogenesis. In *Cancer Medicine* (ed. J.F. Holland, R.C. Bast, Jr., D.L. Morton, E. Frei III, D.W. Kufe, and R.R. Weichselbaum), pp 181–204. Williams & Wilkins, Baltimore, MD.
- Folkman, J., K. Watson, D. Ingber, and D. Hanahan. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* **339**: 58–61.
- Fontanini, G., L. Boldrini, S. Vignati, S. Chine, F. Basolo, V. Silvestri, M. Lucchi, A. Mussi, C.A. Angeletti, and G. Bevilacqua. 1998. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. *Eur. J. Cancer.* **34**: 718–723.
- Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor1. *Mol. Cell. Biol.* **16**: 4604–4613.
- Giaccia, A.J. and M.B. Kastan. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. *Genes & Dev.* **12**: 2973–2983.
- Gimbrone, M.A.J., S.B. Leapman, R.S. Cotran, and J. Folkman. 1972. Tumor dormancy in vivo by prevention of neovascularization. *J. Exp. Med.* **136**: 261–276.
- Goldman, C.K., R.L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G.Y. Gillespie, G.P. Siegal, X. Mao, A.J. Bett, W.R. Huckle et al. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. *Proc. Natl. Acad. Sci.* **95**: 8795–8800.
- Graeber, T.G., C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe, and A.J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature* **379**: 88–91.
- Guillemin, K., and M.A. Krasnow. 1997. The hypoxic response: Huffing and HIFing. *Cell* **89**: 9–12.
- Hanahan, D. and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* **86**: 353–364.
- Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. *Nature* **387**: 299–303.
- Hershko, A. and A. Ciechanover. 1998. The ubiquitin system. *Annu. Rev. Biochem.* **67**: 425–479.
- Holmgren, L., M.S. O'Reilly, and J. Folkman. 1995. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nature Med.* **1**: 149–153.
- Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.* **420**: 25–27.
- Huang, L.E., J. Gu, M. Schau, and H.F. Bunn. 1998. Regulation of hypoxia-inducible factor 1 α is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway. *Proc. Natl. Acad. Sci.* **95**: 7987–7992.
- Iyer, N.V., L.E. Kotch, F. Agani, S.W. Leung, E. Laughner, R.H. Wenger, M. Gassmann, J.D. Gearhart, A.M. Lawler, A.Y. Yuet et al. 1998. Cellular and developmental control of O₂ homeostasis by hypoxia inducible factor1 α . *Genes & Dev.* **12**: 149–162.
- Jiang, B.-H., E. Rue, G.L. Wang, R. Roe, and G.L. Semenza. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. *J. Biol. Chem.* **271**: 17771–17778.
- Jiang, B.-H., F. Agani, A. Passaniti, and G.L. Semenza. 1997. V-SRC induces expression of hypoxia-inducible factor1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. *Cancer Res.* **57**: 5328–5335.
- Kallio, P.J., W.J. Wilson, S. O'Brien, Y. Makino, and L. Poellinger. 1999. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. *J. Biol. Chem.* **274**: 6519–6525.
- Kim, K.J., B. Li, J. Winer, M. Armanini, N. Gillett, H.S. Phillips, and N. Ferrara. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature* **362**: 841–844.

- Kotch, L.E., N.V. Iyer, E. Laughner, and G.L. Semenza. 1999. Defective vascularization of HIF-1 α -null embryos is not associated with VEGF deficiency but with mesenchymal cell death. *Dev. Biol.* **209**: 254–267.
- Kubbutat, H.M.G., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. *Nature* **387**: 299–303.
- Kubbutat, M.H.G., R.L. Ludwig, A.J. Levine, and K.H. Vousden. 1999. Analysis of the degradation function of Mdm2. *Cell Growth & Diff.* **10**: 87–92.
- Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. *Cell* **88**: 323–331.
- Lin, J., J. Chen, B. Elenbaas, and A.J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. *Genes & Dev.* **8**: 1235–1246.
- Lowe, S.W. 1995. Cancer therapy and p53. *Curr. Opin. Oncol.* **7**: 547–553.
- Marston, N.J., J.R. Jenkins, and K.H. Vousden. 1995. Oligomerization of full-length p53 contributes to the interaction with mdm2 but not HPV E6. *Oncogene* **10**: 1709–1715.
- Maxwell, P.H., G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.L. Harris, I.J. Stratford, O. Hankinson, C.W. Pugh, and P.J. Ratcliffe. 1997. Hypoxia-inducible factor 1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. *Proc. Natl. Acad. Sci.* **94**: 8104–8109.
- Maxwell, P.H., M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E. Cockman, C.C. Wykoff, C.W. Pugh, E.R. Maher, and P.J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399**: 271–275.
- Mazure, N.M., E.Y. Chen, K.R. Laderoute, and A.J. Giaccia. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. *Blood* **90**: 3322–3331.
- Millauer, B., L.K. Shawver, K.H. Plate, W. Risau, and A. Ullrich. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. *Nature* **367**: 576–579.
- Millauer, B., M.P. Longhi, K.H. Plate, L.K. Shawver, W. Risau, A. Ullrich, and L.M. Strawn. 1996. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. *Cancer Res.* **56**: 1615–1620.
- Momand, J., G.P. Zambetti, D.L. George, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell* **69**: 1237–1245.
- Mukhopadhyay, D., L. Tsiokas, and V.P. Sukhatme. 1995. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. *Cancer Res.* **55**: 6161–6165.
- Musti, A.M., M. Treier, and D. Bohmann. 1997. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. *Science* **275**: 400–402.
- O'Reilly, M.S., L. Holmgren, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. *Nature Med.* **2**: 689–692.
- Parangi, S., M.S. O'Reilly, G. Christofori, I. Holmgren, J. Grosfeld, J. Folkman, and D. Hanahan. 1996. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. *Proc. Natl. Acad. Sci.* **93**: 2002–2007.
- Plate, K.H., G. Breier, H.A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. *Nature* **359**: 845–848.
- Ravi, R., B. Mookerjee, Y.V. Hensbergen, G.C. Bedi, A. Giodano, W.S. El-Deiry, E.J. Fuchs, and A. Bedi. 1998. p53-mediated repression of nuclear factor κ -B RelA via the transcriptional integrator p300. *Cancer Res.* **58**: 4531–4536.
- Risau, W. and I. Flamme. 1995. Vasculogenesis. *Annu. Rev. Cell Dev. Biol.* **11**: 73–91.
- Ryan, H.E., J. Lo, and R.S. Johnson. 1998. HIF-1 α is required for solid tumor formation and embryonic vascularization. *EMBO J.* **17**: 3005–3015.
- Salceda, S. and J. Caro. 1997. Hypoxia-inducible factor 1 α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. *J. Biol. Chem.* **272**: 22642–22647.
- Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* **63**: 1129–1136.
- Scheffner, M., U. Nuber, and J.M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. *Nature* **373**: 81–83.
- Semenza, G.L. 1999. Regulation of mammalian oxygen homeostasis by hypoxia-inducible factor 1. *Annu. Rev. Cell Dev. Biol.* **15**: 551–578.
- Semenza, G.L. and G.L. Wang. 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol. Cell. Biol.* **12**: 5447–5454.
- Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* **359**: 843–845.
- Van Meir, E.G., P.J. Polverini, V.R. Chazin, H.-J. Su Huang, N. de Tribolet, and W.K. Cavenee. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. *Nature Genet.* **8**: 171–176.
- Wang, G.L. and G.L. Semenza. 1993. Characterization of hypoxia-inducible factor-1 and regulation of DNA binding activity by hypoxia. *J. Biol. Chem.* **268**: 21513–21518.
- Wang, G.L., B.-H. Jiang, E.A. Rue, and G.L. Semenza. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc. Natl. Acad. Sci.* **92**: 5510–5514.
- Warren, R.S., H. Yuan, M.R. Matli, N.A. Gillett, and N. Ferrara. 1995. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. *J. Clin. Invest.* **95**: 1789–1797.
- Wu, X.W., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53 mdm-2 autoregulatory feedback loop. *Genes & Dev.* **7**: 1126–1132.
- Zhong H., A.M. DeMarzo, E. Laughner, M. Lim, A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, and J.W. Simons. 1999. Overexpression of hypoxia-inducible factor 1 α in common human cancers and their metastases. *Cancer Res.* **59**: 5830–5835.